DocuSign Envelope ID: F1DC691D-4C33-4ED4-97DA-4CA0AA87CEFA

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2020 OF THE CONDITION AND AFFAIRS OF THE

AMERIGROUP lowa, Inc.

NAIC Group Code	0671 0671 NAIC Cor (Current) (Prior)	mpany Code 15807	Employer's ID Number	47-3863197		
Organized under the Laws of	lowe	, State of Domici	le or Port of Entry	IA		
Country of Domicile	Un	ited States of America				
Licensed as business type	Health	Maintenance Organization				
Is HMO Federally Qualified? Yes [] No	[X]					
Incorporated/Organized		Commencer	: Business	04/01/2018		
Statutory Home Office4800 W	estown Parkwey, Bldg. 3, Suite 200			oines, IA, US 50266		
	(Street and Number)		(City or Town, Stat	ie, Country and Zip Code)		
Main Administrative Office		25 Corporation Lane Street and Number)				
	, VA, US 23462			-490-6900		
(City or Town, State, I	Country and Zip Code)		(Area Code)	(Telephone Number)		
	25 Corporation Lane	,		ach, VA, US 23462		
(Street	and Number or P.O. Box)		(City or Town, Stat	te, Country and Zip Code)		
Primary Location of Books and Records		425 Corporation Lana				
Viminia Beach	, VA, US 23462	Street and Number)	761	-490-6900		
	Country and Zip Code)			(Telephone Number)		
Internet Website Address		ww.amerigroup.com				
		www.amengroup.com				
Statutory Statement Contact	Bette Lou Gronseth (Name)	· · · · · · · · · · · · · · · · · · ·	ilan C	757-518-3638 ode) (Telephone Number)		
Bette Gronsethg	(marner) manigroup.com			r-557-6742		
(E-mail	Address)		(FA	X Number)		
		OFFICERS				
Chairperson and President	Jeffrey Daniel Jones		Secretary	Kathleen Susan Klefer		
Vice President and			-			
Assistant Secretary	Jack Louis Young		Treasurer	Vincent Edward Scher		
	_	OTHER				
Eric (Rick) Kenneth Noble, Assistent	Treasurer			,		
		TORS OR TRUSTEES				
Jack Louis Young		Jeffrey Daniel Jones		Britteny Lynn Dreke		
State of lowe County of Polk	SS:					
Codality of						
The set of the second state of the second stat						
all of the herein described assets were the	y swom, each depose and say that t absolute property of the said report	they are the described offic iting entity, free and clear	ers of said reporting entity from any liens or claims	y, and that on the reporting period stated above, thereon, except as herein stated, and that this		
statement, together with related exhibits, sol	nedules and explanations therein co	ntained, annexed or referre	rd to, is a full and true sta	tement of all the assets and liabilities and of the for the period ended, and have been completed		
in accordance with the NAIC Annual Staten	nent Instructions and Accounting Pr	inclices and Procedures m	anual except to the exten	t that: (1) state law may differ; or, (2) that state		
rules or regulations require differences in respectively. Furthermore the scope of this	reporting not related to accounting attastation by the described office	ig practices and procedure also includes the related	les, according to the be	st of their information, knowledge and belief, c filing with the NAIC, when required, that is an		
exact copy (except for formatting differences	a due to electronic filing) of the enclo	used statement. The electr	onic filing may be reques	ted by various regulators in lieu of or in addition		
o matericities has mont		l. Sahar	(Alogen there to		
Jeffrey D. Jones				arguing a ruger		
EFBA9711281E45C Jeffray Daniel Jones	A85A337220	4143E	-	Kathleen Susan Kiefer		
Chairperson and President	Ŷ	Treasurer		Secretary		
				*		
		a, la this i	en original filing?	Yes [X] No []		
Subscribed and sworn to before me this	1 00	b. If no,				
day of	corugry, alo		e the amendment number	r		
0	A	Z. Date 3. Nun	a filed			
2017	X V Ulije					
(Jacquer /	1. Luch ha					

Commission Number 750014 My Commission Expires November 20, 2022

	AS	SETS			
		·	Current Year	-	Prior Year
		1	2	3 Net Admitted Assets	4 Net Admitted
		Assets	Nonadmitted Assets	(Cols. 1 - 2)	Assets
1.	Bonds (Schedule D)				
2.	Stocks (Schedule D):				
	2.1 Preferred stocks			0	
	2.2 Common stocks			_	
3.	Mortgage loans on real estate (Schedule B):				
5.				0	
	3.1 First liens				
	3.2 Other than first liens			0 .	
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$				
	encumbrances)			0	
	4.2 Properties held for the production of income (less				
	\$ encumbrances)			0	
	4.3 Properties held for sale (less \$				
	encumbrances)			0	
-					
5.	Cash (\$(7,408,716) , Schedule E - Part 1), cash equivalents				
	(\$0 , Schedule E - Part 2) and short-term				
	investments (\$				
	Contract loans, (including \$ premium notes)				
7.	Derivatives (Schedule DB)			0	
8.	Other invested assets (Schedule BA)			0	
9.	Receivables for securities			0	
10.	Securities lending reinvested collateral assets (Schedule DL)				
	Aggregate write-ins for invested assets				
	Subtotals, cash and invested assets (Lines 1 to 11)				
			0		
13.	Title plants less \$ charged off (for Title insurers			0	
	only)				
14.	Investment income due and accrued		0	3,805,976	2,348,105
15.	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection		0		
	15.2 Deferred premiums and agents' balances and installments booked but				
	deferred and not yet due (including \$				
	earned but unbilled premiums)			0	
	15.3 Accrued retrospective premiums (\$				
	contracts subject to redetermination (\$			0	0
40					
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers				
	16.2 Funds held by or deposited with reinsured companies				
	16.3 Other amounts receivable under reinsurance contracts				
	Amounts receivable relating to uninsured plans				
18.1	Current federal and foreign income tax recoverable and interest thereon			0	
18.2	Net deferred tax asset			5,056,826	4,300,942
19.	Guaranty funds receivable or on deposit			0	
20.	Electronic data processing equipment and software			0	
20.	Furniture and equipment, including health care delivery assets				
£1.	(\$	1 116 600	1 116 600	n	٥
22	(0
23.	Receivables from parent, subsidiaries and affiliates				
24.	Health care (\$0) and other amounts receivable				
25.	Aggregate write-ins for other than invested assets			0	
26.	Total assets excluding Separate Accounts, Segregated Accounts and	000 700 404	44 407 700	070 505 700	6FF 000 400
	Protected Cell Accounts (Lines 12 to 25)		14 , 187 , 726	ช/๖,๖३๖,/๖୪	
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			0	
28.	Total (Lines 26 and 27)	890,723,494	14,187,726	876,535,768	655,669,190
20.		550,720,434	1, 107, 720	070,000,700	500,000,100
	DETAILS OF WRITE-INS				
1101.					
1102.					
1103.					
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0	0
	Prepaid Expenses	12 050	42.059	0	0
	State Income Taxes Paid in Advance				
2502.					,
2503.					
2598.	Summary of remaining write-ins for Line 25 from overflow page			0	
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	42,059	42,059	0	50,000

ASSETS

LIABILITIES, CAPITAL AND SURPLUS

		1	Current Year 2	3	Prior Year 4
				-	
4		Covered	Uncovered	Total	Total
1. 2.	Claims unpaid (less \$0 reinsurance ceded) Accrued medical incentive pool and bonus amounts				
2. 3.	Unpaid claims adjustment expenses.				
3. 4.	Aggregate health policy reserves, including the liability of				
4.	\$				
	Health Service Act			0	
5.	Aggregate life policy reserves.				
5. 6.	Property/casualty unearned premium reserves.				
0. 7.	Aggregate health claim reserves.				
7. 8.	Premiums received in advance				
0. 9.	General expenses due or accrued				
10.1					
10.1	(including \$	1 970 199		1 970 199	15 742 109
10.2	Net deferred tax liability				
11.	Ceded reinsurance premiums payable				
12.	Amounts withheld or retained for the account of others.				
13.	Remittances and items not allocated				
14.	Borrowed money (including \$				
14.	interest thereon \$				
	\$			0	
15.	Amounts due to parent, subsidiaries and affiliates				
	Derivatives.				
16.					
17.	Payable for securities				
18.	Payable for securities lending				2,409,425
19.	Funds held under reinsurance treaties (with \$				
	reinsurers and \$			0	
00					
20.	Reinsurance in unauthorized and certified (\$)			0	
	companies				
21.	Net adjustments in assets and liabilities due to foreign exchange rates				
22.	Liability for amounts held under uninsured plans				
23.	Aggregate write-ins for other liabilities (including \$	4 047 500		4 9 47 599	
	current)		0		1,116,491
24.	Total liabilities (Lines 1 to 23)		0		
25.	Aggregate write-ins for special surplus funds		XXX		
26.	Common capital stock				10
27.	Preferred capital stock				
28.	Gross paid in and contributed surplus				
29.	Surplus notes				
30.	Aggregate write-ins for other than special surplus funds				
31.	Unassigned funds (surplus)	XXX	XXX	43,588,845	(179,142,095)
32.	Less treasury stock, at cost:				
	32.1 shares common (value included in Line 26				
	\$	XXX	XXX		
	32.2 shares preferred (value included in Line 27				
	\$	XXX	XXX		
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)	XXX	XXX		
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	876,535,768	655,669,190
	DETAILS OF WRITE-INS				
2301.	Escheat Liability	1,142,382		1,142,382	
2302.	Other Premium Liability				
2303.					
2398.	Summary of remaining write-ins for Line 23 from overflow page	0	0	0	0
2399.	Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	1,247,529	0	1,247,529	1,116,491
2501.	Estimated ACA Health Insurer fee				
2502.					
2503.					
	Summary of remaining write-ins for Line 25 from overflow page				0
	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	0	37,039,805
					- ,, -
3002. 3003.					
	Summary of remaining write-ins for Line 30 from overflow page			0	
3002					0

STATEMENT OF REVENUE AND EXPENSES

		Current		Prior Year
		1 Uncovered	2 Total	3 Total
1. Member M	onths		4,869,966	
	n income (including \$			
	inearned premium reserves and reserve for rate credits			
	rice (net of \$ medical expenses)			
	e			
00 0	vrite-ins for other health care related revenues			
	vrite-ins for other non-health revenues			
8. Total reven	ues (Lines 2 to 7)	XXX	3,314,084,433	2,380,138,249
Hospital ar 9. Hospital/me	d Medical: dical benefits		1 066 810 000	1 422 620 044
	ssional services			
	errals			
	room and out-of-area			
	drugs			, ,
	vrite-ins for other hospital and medical			
	ol, withhold adjustments and bonus amounts			
-	nes 9 to 15)	0	2,848,655,529	
Less:			0	
	ince recoveries			
	al and medical (Lines 16 minus 17)			
	claims (net)			
-	stment expenses, including \$			
	ninistrative expenses			
	reserves for life and accident and health contracts (including \$			
	in reserves for life only)			
	writing deductions (Lines 18 through 22)			
	riting gain or (loss) (Lines 8 minus 23)			
	ent income earned (Exhibit of Net Investment Income, Line 17)			
	capital gains (losses) less capital gains tax of \$		2,142,364	1,659,902
	ent gains (losses) (Lines 25 plus 26)	0		
28. Net gain or	(loss) from agents' or premium balances charged off [(amount recovered			
) (amount charged off \$			
29. Aggregate	vrite-ins for other income or expenses	0		
30. Net income 27 plus 28	or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus plus 29)	xxx	247.962.828	
	foreign income taxes incurred			
	(loss) (Lines 30 minus 31)	XXX	188,387,801	81,828,108
	F WRITE-INS	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,	01,020,100
	f remaining write-ins for Line 6 from overflow page			0
0699. Totals (Line	s 0601 thru 0603 plus 0698)(Line 6 above)	XXX	0	0
0701		XXX		
0702.				
0703				
0798. Summary o	f remaining write-ins for Line 7 from overflow page		0	0
0799. Totals (Line	s 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
1401. Home Health	care, DME, Transportation, etc.		0	
1402.				
1498. Summary o	f remaining write-ins for Line 14 from overflow page		0	0
	s 1401 thru 1403 plus 1498)(Line 14 above)	0	0	6,789
	us (expense) income			
	f remaining write-ins for Line 29 from overflow page			0
2999. Totals (Line	s 2901 thru 2903 plus 2998)(Line 29 above)	0	868,026	981,004

STATEMENT OF REVENUE AND EXPENSES (Continued)

		1 Current Year	2 Prior Year
	CAPITAL AND SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year		
34.	Net income or (loss) from Line 32		
35.	Change in valuation basis of aggregate policy and claim reserves		
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$		
37.	Change in net unrealized foreign exchange capital gain or (loss)		
38.	Change in net deferred income tax		1,598,371
39.	Change in nonadmitted assets	(3,297,739)	
40	Change in unauthorized and certified reinsurance		
41.	Change in treasury stock		
42.	Change in surplus notes		
43.	Cumulative effect of changes in accounting principles		
44.	Capital Changes:		
	44.1 Paid in	0	
	44.2 Transferred from surplus (Stock Dividend)	0	
	44.3 Transferred to surplus		
45.	Surplus adjustments:		
	45.1 Paid in	0	
	45.2 Transferred to capital (Stock Dividend)		
	45.3 Transferred from capital		
46.	Dividends to stockholders		
47.	Aggregate write-ins for gains or (losses) in surplus	0	0
48.	Net change in capital and surplus (Lines 34 to 47)		
49.	Capital and surplus end of reporting period (Line 33 plus 48)	494,588,845	308,897,710
	DETAILS OF WRITE-INS		
4701.			
4702.			
4703.			
4798.	Summary of remaining write-ins for Line 47 from overflow page	0	0
4799.	Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	0	0

CASH FLOW

		1	2
		Current Year	Prior Year
	Cash from Operations		
1.	Premiums collected net of reinsurance		
2.	Net investment income		
3.	Miscellaneous income	0	
4.	Total (Lines 1 through 3)		2,463,594,169
5.	Benefit and loss related payments	2,840,773,917	1,991,779,227
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7.	Commissions, expenses paid and aggregate write-ins for deductions		
8.	Dividends paid to policyholders		
9.	Federal and foreign income taxes paid (recovered) net of \$546,495 tax on capital gains (losses)		9,013,963
10.	Total (Lines 5 through 9)		2,119,627,538
11.	Net cash from operations (Line 4 minus Line 10)	133,520,975	343,966,631
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
	12.1 Bonds		
	12.2 Stocks	0	
	12.3 Mortgage loans	0	
	12.4 Real estate	0	
	12.5 Other invested assets	0	
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments	(105,488)	
	12.7 Miscellaneous proceeds		
	12.8 Total investment proceeds (Lines 12.1 to 12.7)		
13.	Cost of investments acquired (long-term only):		
	13.1 Bonds		
	13.2 Stocks	0	
	13.3 Mortgage loans	0	
	13.4 Real estate	0	
	13.5 Other invested assets	0	
	13.6 Miscellaneous applications	33,579,647	2,409,425
	13.7 Total investments acquired (Lines 13.1 to 13.6)	748,057,016	634,969,456
14.	Net increase (decrease) in contract loans and premium notes	0	
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(400,112,674)	(348,020,994)
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes	0	
	16.2 Capital and paid in surplus, less treasury stock	0	
	16.3 Borrowed funds	0	
	16.4 Net deposits on deposit-type contracts and other insurance liabilities	0	
	16.5 Dividends to stockholders	0	
	16.6 Other cash provided (applied)		6,938,450
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	27,329,685	61,938,450
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	(239,262,014)	57,884,087
19.	Cash, cash equivalents and short-term investments:	,,,	- ,,-**
	19.1 Beginning of year	231,853,298	
	19.2 End of year (Line 18 plus Line 19.1)	(7,408,716)	231,853,298
		(.,,	, 300, 200
	upplemental disclosures of cash flow information for non-cash transactions:		
	1 Depreciation	260 171	300 200

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

 Chan rate Fee-formed Risk n Aggreare Aggreare Aggreare Aggreare Aggreare Total Hospi Other Other Outesi Emeritation Aggreare Aggreare Aggreare Chaim Gene Increare 	premium income	<u>Total</u> 3,314,084,433 0 0 0	Comprehensive (Hospital & Medical) 75,058,643 0	Medicare Supplement	Dental Only 	Vision Only	Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other Health	Other Non-Health
 Chan rate Fee-formed Risk n Aggreare Aggreare Aggreare Aggreare Aggreare Total Hospi Other Other Outesi Emeritation Aggreare Aggreare Aggreare Chaim Gene Increare 	inge in unearned premium reserves and reserve for e credit		(0	(10	0			Hon Hodian
 Chan rate Fee-formed Risk n Aggreare Aggreare Aggreare Aggreare Aggreare Total Hospi Other Other Outesi Emeritation Aggreare Aggreare Aggreare Chaim Gene Increare 	inge in unearned premium reserves and reserve for e credit		0	0	0					0	0
 med 4. Risk n 5. Aggre reve 6. Aggre reve 7. Total 8. Hospi 9. Other 10. Outsi 11. Emer 12. Preso 13. Aggre 14. Incen 15. Subto 16. Net re 17. Total 18. Non-f 19. Claim \$ 20. Gene 21. Increat 	-for-service (net of \$0 edical expenses)	0 0					0			0	0
 Risk r Aggre reve Aggre reve Aggre reve Total Hospi Other Outsi Emer Preso Aggre reso Aggre reso Aggre reso Aggre reso Aggre reso Net re Non-1 Non-1 Claim \$ Gene 21. Increa 	<pre>c revenue</pre>	D									
 reve Aggre reve Total Hospi Ottsi Emer Presc Aggre Aggre Aggre Aggre Aggre Aggre Aggre Net re Subtc Net re Total Non-f Claim Sume Gene Increation 	regate write-ins for other non-health care related										
 reve 7. Total 8. Hospi 9. Other 10. Outsi 11. Emer 12. Presc 13. Aggre 14. Incen 15. Subto 16. Net re 17. Total 18. Non-f 19. Claim \$ 20. Gene 21. Increation 		0	0	0	0		٥٥	o	0	0	
7. Total 8. Hospi 9. Other 10. Outsi 11. Emer 12. Preso 13. Aggre 14. Incen 15. Subto 16. Net re 17. Total 18. Non-f 19. Claim \$		0	xxx	xxx	xxx	xxx	XXX	xxx	XXX	xxx	0
8. Hospi 9. Other 10. Outsi 11. Emer 12. Presc 13. Aggre 14. Incen 15. Subto 16. Net re 17. Total 18. Non-H 19. Claim \$	al revenues (Lines 1 to 6)	3.314.084.433	75.058.643	0	0	0		0	3,239,025,790	0	0
9. Other 10. Outsi 11. Emer 12. Presc 13. Aggre 14. Incen 15. Subto 16. Net re 17. Total 18. Non-H 19. Claim \$	pital/medical benefits	1,966,812,200		0	0	(اه	Ő	1,931,617,135	0	XXX
10. Outsin 11. Emer 12. Preso 13. Aggre 14. Incen 15. Subto 16. Net re 17. Total 18. Non-H 19. Claim \$	er professional services			0	0	0	ا م	Ő	.285,050,969	0	XXX
11. Emer 12. Presc 13. Aggre 14. Incen 15. Subto 16. Net re 17. Total 18. Non-t 19. Claim \$	side referrals			0	0	0	ا م	Ő	0	0	XXX
12. Presc 13. Aggre 14. Incen 15. Subto 16. Net re 17. Total 18. Non-t 19. Claim \$	ergency room and out-of-area			0	0	0	٥	0		0	XXX
 Incen Subto Net re Non-ł Non-ł Claim Claim Gene Increa 	scription drugs	412,929,753	13,569,279	0	0	<u>ر</u>	٥ (I		399,360,474	0	XXX
 Incen Subto Net re Non-ł Non-ł Claim Claim Gene Increa 	regate write-ins for other hospital and medical		0		0		٥	0	0		XXX
15. Subto 16. Net re 17. Total 18. Non-F 19. Claim 20. Gene 21. Increase	entive pool, withhold adjustments and bonus amounts	.28,553,233	.203,874	0	0	<u>ر</u>	٥ (I		.28,349,359		XXX
16. Net re 17. Total 18. Non-h 19. Claim 20. Gene 21. Increase	total (Lines 8 to 14)	2,848,655,529		0	0		٥ (I		2,789,763,638	0	XXX
17. Total 18. Non-h 19. Claim \$ 20. Gene 21. Increa	reinsurance recoveries	.0	0	0	0	(٥	0	0	0	XXX
18. Non-ł 19. Claim \$ 20. Gene 21. Increa	al medical and hospital (Lines 15 minus 16)	2,848,655,529	.58,891,891	0	0	(٥	0	2,789,763,638	0	XXX
19. Claim \$ 20. Gene 21. Increa	-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
\$ 20. Gene 21. Increa	ms adjustment expenses including										
21. Increa			.6,289,148		0	0	٥	0	105,413,872	0	0
	eral administrative expenses	123,449,099	.6,950,481		0	0	٥	0	116,498,618	0	0
22 Inorod	ease in reserves for accident and health contracts		0		0	0	٥	0	0	0	XXX
	ease in reserves for life contracts	0		XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
23. Total	al underwriting deductions (Lines 17 to 22)	.3,083,807,648			0	0	٥	0	3,011,676,128	0	0
24. Total	al underwriting gain or (loss) (Line 7 minus Line 23)	230,276,785	2,927,123	0	0	(0	0	227,349,662	0	0
DETA	TAILS OF WRITE-INS										XXX
0503.											
page		0	0	0	0		٥٥	0	0	0	
0599. Totals	als (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0) 0	0	0	0	XXX
0601			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0002.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0603	······		XXX	XXX	XXX	XXX		XXX	XXX	XXX	
	nmary of remaining write-ins for Line 6 from overflow										
page 0699. Totals	ge als (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0 0	XXX XXX	XXX	XXX XXX			XXX XXX	XXX	XXX	0 0
1301			,,,,,								
											XXX
1303.											
1398. Sumr			11		••••••	1				·····	
1399. Totals	nmary of remaining write-ins for Line 13 from erflow page	0	0	0	٥		۱ <u>۱</u>	٥	0	n	XXX

7

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
1. Comprehensive (hospital and medical)		0	0	
2. Medicare Supplement	0	0	0	0
3. Dental only	0	0	0	0
4. Vision only	0	0	0	0
5. Federal Employees Health Benefits Plan	0	0	0	0
6. Title XVIII - Medicare	0	0	0	0
7. Title XIX - Medicaid		0	0	3,239,025,790
8. Other health	0	0	0	0
9. Health subtotal (Lines 1 through 8)		0	0	3,314,084,433
10. Life	0		0	0
11. Property/casualty	0			0
12. Totals (Lines 9 to 11)	3,314,084,433	0	0	3,314,084,433

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

		1 Total	2 Comprehensive (Hospital & Medical)	3 Medicare Supplement	4 Dental Only	5 Vision Only	6 Federal Employees Health Benefits Plan	7 Title XVIII Medicare	8 Title XIX Medicaid	9 Other Health	10 Other Non-Health
1	Payments during the year:	Total		Supplement	Dental Only	VISION ONLY	Denents Fildri	Wedicare	Wealcald	Other freditin	Non-meanin
	1.1 Direct	2,833,513,241							2,776,376,779		
	1.2 Reinsurance assumed	0							, , , ,		
	1.3 Reinsurance ceded	0									
	1.4 Net	2,833,513,241		0	0	0	0	0		0	(
	Paid medical incentive pools and bonuses		129,590						7,131,087		
	Claim liability December 31, current year from Part 2A:	,,							·····		
	3.1 Direct			0	0	0	0	0		0	(
	3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	(
	3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	(
	3.4 Net		5,375,194	0	0	0	0	0	278,825,587	0	(
	Claim reserve December 31, current year from Part 2D:										
	4.1 Direct										
	4.2 Reinsurance assumed										
	4.3 Reinsurance ceded	0									
	4.4 Net		0	0	0	0	0	0		0	(
5	Accrued medical incentive pools and bonuses, current										
5.	year										
6.	Net healthcare receivables (a)		(77,588)						3.910.677		
	Amounts recoverable from reinsurers December 31, current year	0	,								
8.	Claim liability December 31, prior year from Part 2A:										
	8.1 Direct			0	0	0	0	0		0	
	8.2 Reinsurance assumed	0		.0	0	0	0	0		.0	
	8.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	
	8.4 Net			0	0	0	0	0		0	
	Claim reserve December 31, prior year from Part 2D:	,.,.,.	, ,								
	9.1 Direct	203.428							203.428		
	9.2 Reinsurance assumed								, 		
	9.3 Reinsurance ceded	0									
	9.4 Net	.203,428	0	0	0	0	0	0	203,428	0	(
	Accrued medical incentive pools and bonuses, prior year	4,846,140							4,846,140		
	Amounts recoverable from reinsurers December 31, prior year	0							.,,		
12.	Incurred Benefits:										
	12.1 Direct	2,820,102,296		0	0	0	0	0	2,761,414,279		
	12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	(
	12.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	(
	12.4 Net	2,820,102,296	58,688,017	0	0	0	0	0	2,761,414,279	0	(
13	Incurred medical incentive pools and bonuses	28,553,233	203.874	0	0 0	0	0	0	28.349.359	0 N	(

(a) Excludes \$ loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

	4						7	0	0	40
	1	2	3	4	5	6 Federal Employees	7 Title	8 Title	9	10
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Health Benefits Plan	XVIII Medicare	XIX Medicaid	Other Health	Other Non-Health
1. Reported in Process of Adjustment:										
1.1 Direct										
1.2 Reinsurance assumed	0									
1.3 Reinsurance ceded	0									
1.4 Net			0	0	0	0	0		0	0
2. Incurred but Unreported:										
2.1 Direct		4,483,659								
2.2 Reinsurance assumed	0									
2.3 Reinsurance ceded	0									
2.4 Net		4,483,659	0	0	0	0	0		0	0
3. Amounts Withheld from Paid Claims and Capitations:										
3.1 Direct	0									
3.2 Reinsurance assumed	0									
3.3 Reinsurance ceded	0									
3.4 Net	0	0	0	0	0	0	0	0	0	0
4. TOTALS:										
4.1 Direct		5,375,194	0	0	0	0	0		0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
4.4 Net	284,200,781	5,375,194	0	0	0	0	0	278,825,587	0	0

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

	Claims Paid D	During the Year	Claim Reserve a December 31		5	6
Line of Business	1 On Claims Incurred Prior to January 1 of Current Year	2 On Claims Incurred During the Year	3 On Claims Unpaid December 31 of Prior Year	4 On Claims Incurred During the Year	Claims Incurred In Prior Years (Columns 1 + 3)	Estimated Claim Reserve and Claim Liability December 31 of Prior Year
1. Comprehensive (hospital and medical)				5,307,740		
2. Medicare Supplement					0	0
3. Dental Only					0	0
4. Vision Only					0	0
5. Federal Employees Health Benefits Plan					0	0
6. Title XVIII - Medicare					0	0
7 Title XIX - Medicaid		2,490,798,623	(6,229,402)			
8. Other health					0	0
9. Health subtotal (Lines 1 to 8)		2,544,430,453	(6,161,948)			
10. Healthcare receivables (a)		6,780,111				0
11. Other non-health					0	0
12. Medical incentive pools and bonus amounts		191,481	2,069,445	24,069,251	9, 138,641	4,846,140
13. Totals (Lines 9 - 10 + 11 + 12)	299,099,006	2,537,841,823	(4,092,503)	314,653,421	295,006,503	298,846,218

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

	Cumulative Net Amounts Paid					
	1	2	3	4	5	
Year in Which Losses Were Incurred	2016	2017	2018	2019	2020	
1. Prior	0	0	0	0		
2. 2016						
3. 2017	XXX					
4. 2018						
5. 2019	XXX					
6. 2020	XXX	XXX	XXX	XXX	53,658	

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

	Sum of Cumulative Net	Amount Paid and Clain Outs	n Liability, Claim Rese standing at End of Yea	erve and Medical Incentive ar	Pool and Bonuses
Year in Which Losses Were Incurred	1 2016	2 2017	3 2018	4 2019	5 2020
1. Prior			0		
2. 2016					
3. 2017	XXX				
4. 2018	XXX	XXX			
5. 2019	XXX	XXX	XXX		
6. 2020	XXX	XXX	XXX	XXX	59,040

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

		1	2	3	4	5 Claim and Claim	6	7	8	9 Total Claima and	10
	Years in which					Adjustment Expense			Unpaid Claims	Total Claims and Claims Adjustment	
	Premiums were Earned and Claims were Incurred	Premiums Earned	Claims Payment	Claim Adjustment Expense Payments	(Col. 3/2) Percent	Payments (Col. 2 + 3)	(Col. 5/1) Percent	Claims Unpaid	Adjustment Expenses	Expense Incurred (Col. 5+7+8)	(Col. 9/1) Percent
1.	2016	12,276	9,819	1,430				0			
2.	2017			1,964							
3.	2018							(13)			
4.	2019			4,597							
5.	2020	75,059	53,658	5,463	10.2	59,121	78.8	5,382	137	64,640	86.1

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Title XIX

		Cumi	lative Net Amounts P	Paid	
	1	2	3	4	5
Year in Which Losses Were Incurred	2016	2017	2018	2019	2020
1. Prior	0	0	0	0	0
2. 2016					
3. 2017			1,215,057	1,215,307	1,213,923
4. 2018			1,207,666	1,320,772	
5. 2019				1,840,684	
6. 2020	XXX	XXX	XXX	XXX	2,484,184

Section B -	 Incurred 	Health	Claims -	Title XIX
-------------	------------------------------	--------	----------	-----------

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year						
Year in Which Losses Were Incurred	1 2016	2 2017	3 2018	4 2019	5 2020		
1. Prior	0	0	0		0		
2. 2016							
3. 2017	XXX	1,233,667			1,214,054		
4. 2018	XXX				1,321,230		
5. 2019	XXX	XXX	xxx				
6. 2020	XXX	XXX	XXX	XXX	2,793,456		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XIX

		1	2	3	4	5	6	7	8	9	10
	Years in which					Claim and Claim Adjustment Expense			Unpaid Claims	Total Claims and Claims Adjustment	
	Premiums were Earned and Claims were Incurred	Premiums Earned	Claims Payment	Claim Adjustment Expense Payments	(Col. 3/2) Percent	Payments (Col. 2 + 3)	(Col. 5/1) Percent	Claims Unpaid	Adjustment Expenses	Expense Incurred (Col. 5+7+8)	(Col. 9/1) Percent
1	2016	775.713	891.155	55.886	6.3	947.041	122.1	484	12	947.537	122.2
2.	2017		1,213,923	, ,	4.6					1,270,168	
3.	2018	1,428,226	1,323,317	57.880	4.4	1,381,197	96.7	(2,087)	(52)	1,379,058	.96.6
4.	2019	2,333,211						(2,689)			
5.	2020	3,239,026	2,484,184	90,437	3.6	2,574,621	79.5	309,272	7,174	2,891,067	89.3

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

(\$000 Omitted)

Section A - Paid Health Claims - Grand Total

		Cumu	Ilative Net Amounts P	Paid	
	1	2	3	4	5
Year in Which Losses Were Incurred	2016	2017	2018	2019	2020
1. Prior	0		0		0
2. 2016					
3. 2017		1,111,891	1,232,391		1,231,223
4. 2018			1,223,835		1,340,622
5. 2019			XXX	1,879,782	2, 179, 329
6. 2020	XXX	XXX	XXX	XXX	2,537,842

Section	B - Incurred	d Health C	Claims - (Grand Total	
00001011	D mounes				

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year					
Year in Which Losses Were Incurred	1 2016	2 2017	3 2018	4 2019	5 2020	
1. Prior	.0				.0	
2. 2016						
3. 2017	XXX	1,251,132	1,234,492		1,231,355	
4. 2018	XXX	XXX	1,350,817		1,338,522	
5. 2019	XXX	XXX	XXX			
6. 2020	XXX	XXX	XXX	XXX	2,852,496	

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2016										
2.	2017	1,231,185	1,231,223		4.7	1,289,298				1,289,433	
3.	2018	1,445,400				1,400,649		(2,100)	(52)	1,398,497	
4.	2019							(2,610)	(118)		
5.	2020	3,314,085	2,537,842	95,900	3.8	2,633,742	79.5	314,654	7,311	2,955,707	89.2

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	1	2	3	4	5	6	7	8	9
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other
1. Unearned premium reserves	0								
2. Additional policy reserves (a)	0								
3. Reserve for future contingent benefits	0								
4. Reserve for rate credits or experience rating refunds (including									
\$) for investment income	0								
5. Aggregate write-ins for other policy reserves	0	0	0	0	0	0	0	0	
6. Totals (gross)	0	0	0	0	0	0	0	0	
7. Reinsurance ceded	0								
8. Totals (Net)(Page 3, Line 4)			0	0	0	0	0	0	0
9. Present value of amounts not yet due on claims									
10. Reserve for future contingent benefits									
11. Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	
12. Totals (gross)		0	0	0	0	0	0		0
13. Reinsurance ceded	0								
14. Totals (Net)(Page 3, Line 7)	221,441	0	0	0	0	0	0	221,441	(
DETAILS OF WRITE-INS									
0501.									
0502.									
0503.									
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	
0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	(
1101.						ļļ			
1102.						 			
1103.									
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	
1199. Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	(

(a) Includes \$ _____ premium deficiency reserve.

ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Amerigroup Iowa, Inc. UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES 3 4 5 Claim Adjustment Expenses Cost Other Claim General Containment Adjustment Administrative Investment Expenses Expenses Expenses Total Expenses 1. Rent (\$ for occupancy of .1,630,529 .803, 122 .(957,515) .(2,132) .1,474,004 own building) .. .62,273,027 .13,684,276 .31,383,421 .69,865 .107,410,589 Salary, wages and other benefits 2. 3. Commissions (less \$.0 ceded plus \$..0 ..0 ..0 assumed) .1,452 1.105.701 2.461 1.109.614 4. Legal fees and expenses 0 0 5. Certifications and accreditation fees .3,283,225 1,179,533 .7,707,900 .17, 159 .12, 187, 817 6. Auditing, actuarial and other consulting services .288,531 .157,125 .9,672 .350 .455,678 7. Traveling expenses .307,068 .17,202 1,636,739 .3,644 .1,964,653 8. Marketing and advertising .761.802 354.272 1.539.354 .3.427 2.658.855 9. Postage, express and telephone 114,231 2,039 .112,184 250 228.704 10. Printing and office supplies .0 ..0 0 .0 11. Occupancy, depreciation and amortization 179,348 2.113 470.038 1,046 652.545 12. Equipment 13. Cost or depreciation of EDP equipment and software .876.485 .215,651 .7.132.865 .15,879 .8,240,880 Outsourced services including EDP, claims, and 14. 6.064.889 5.228.052 4.150.391 9.239 15.452.571 other services 15. Boards, bureaus and association fees 3.820 263.018 586 267.424 16. Insurance, except on real estate 0 703 781 1 567 705 348 .0 .0 .167 Collection and bank service charges 75.122 75.289 17. (281 3.156 7 2.882 18. Group service and administration fees 0 .0 ..0 .0 .0 19. Reimbursements by uninsured plans 0 0 0 0 20. Reimbursements from fiscal intermediaries 21. 118,317 .47,068 1,383,545 3,080 1,552,010 Real estate expenses 0 128 623 22. Real estate taxes 0 128 623 23. Taxes, licenses and fees: 23.1 State and local insurance taxes .0 20 769 755 0 20 769 755 .0 23.2 State premium taxes . .0 ..0 ...0 0 15.678 74.653 23.3 Regulatory authority licenses and fees 316 58.659 .3,689,143 .801,767 .0 23.4 Payroll taxes .1,830,494 .6,321,404 23.5 Other (excluding federal income and real .0 .38,453,092 .0 38,453,092 estate taxes) 467.079 467.079 0 0 24 Investment expenses not included elsewhere 291,293 9,459,380 5,341,651 11,891 15,104,215 25. Aggregate write-ins for expenses 79.898.838 .605,565 26. Total expenses incurred (Lines 1 to 25) 31.804.182 123,449,099 (a) 235.757.684 7,156,380 .8,376,003 15,532,383 27. Less expenses unpaid December 31, current year 7 096 380 28. Add expenses unpaid December 31, prior year 388.604 7.484.984 29. Amounts receivable relating to uninsured plans, 6 598 000 6 598 000 prior year 30. Amounts receivable relating to uninsured plans, 0 current year Total expenses paid (Lines 26 minus 27 plus 28 31. 79,898,838 31,744,182 108,863,700 605,565 221,112,285 minus 29 plus 30) DETAILS OF WRITE-INS 2501. Miscellaneous Expense 291,293 .9,459,380 .11,891 .5.341.651 15,104,215 2502. 2503. 2598. Summary of remaining write-ins for Line 25 from .0 ..0 .0 0 .0 overflow page 2599. Totals (Lines 2501 thru 2503 plus 2598)(Line 25 9,459,380 5,341,651 11,891 15,104,215 291,293 above)

ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Amerigroup Iowa, Inc. EXHIBIT OF NET INVESTMENT INCOME

[]		1	2
		Collected During Year	Earned During Year
1.	U.S. government bonds		
1.1	Bonds exempt from U.S. tax	· · /	
1.2	Other bonds (unaffiliated)		
1.3	Bonds of affiliates	(a)0	
2.1	Preferred stocks (unaffiliated)		0
2.11	Preferred stocks of affiliates		0
2.2	Common stocks (unaffiliated)		0
2.21	Common stocks of affiliates	0	0
3.	Mortgage loans		
4.	Real estate	(d)0	0
5	Contract Loans		0
6	Cash, cash equivalents and short-term investments	(e)1,285,961	1,285,961
7	Derivative instruments	. (f)0	
8.	Other invested assets		0
9.	Aggregate write-ins for investment income		
10.	Total gross investment income	13,823,346	15,281,218
11.	Investment expenses		(g)605,565
12.	Investment taxes, licenses and fees, excluding federal income taxes		
13.	Interest expense		(h)
14.	Depreciation on real estate and other invested assets		(i)
15.	Aggregate write-ins for deductions from investment income		0
16.	Total deductions (Lines 11 through 15)		
17.	Net investment income (Line 10 minus Line 16)		14,675,653
	DETAILS OF WRITE-INS		
0901.	Miscellaneous Income		
0902.	Securities Lending		
0903.	-		
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	47,149	
1501.			
1502.			
1503.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		0
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		0

(a) Includes \$	
(b) Includes \$	5.
(c) Includes \$	
(d) Includes \$ for company's occupancy of its own buildings; and excludes \$ interest on encumbrances.	
(e) Includes \$	
(f) Includes \$	
(g) Includes \$ investment expenses and \$ investment taxes, licenses and fees, excluding federal income taxes, attributable to segregated and Separate Accounts.	
(h) Includes \$ interest on surplus notes and \$ interest on capital notes.	
(i) Includes \$ depreciation on real estate and \$ depreciation on other invested assets.	

EXHIBIT OF CAPITAL GAINS (LOSSES)

		1	2	3	4	5
				Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds	2,100,253	0	2,100,253	0	0
1.1	Bonds exempt from U.S. tax					
1.2	Other bonds (unaffiliated)	1,040,425	(293,758)		(45,664)	0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	0	0	0	0	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans		0	0	0	0
4.	Real estate			0		0
5.	Contract loans			0		
6.	Cash, cash equivalents and short-term investments	(158,061)		(158,061)		
7.	Derivative instruments			0		
8.	Other invested assets		0	0	0	0
9.	Aggregate write-ins for capital gains (losses)	0	0	0	0	0
10.	Aggregate write-ins for capital gains (losses) Total capital gains (losses)	2,982,617	(293,758)	2,688,859	6,909	0
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from					
	overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9,					
	above)	0	0	0	0	0

ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Amerigroup Iowa, Inc. EXHIBIT OF NON-ADMITTED ASSETS

		1 Current Year Total Nonadmitted Assets	2 Prior Year Total Nonadmitted Assets	3 Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1.	Bonds (Schedule D)		Nonaumilied Assels	
	Stocks (Schedule D):			
۷.	2.1 Preferred stocks			0
	2.2 Common stocks			
3.	Mortgage loans on real estate (Schedule B):			
5.	3.1 First liens			0
	3.2 Other than first liens			0
4				0
4.	Real estate (Schedule A): 4.1 Properties occupied by the company			0
	4.2 Properties held for the production of income			0
	4.3 Properties held for sale			0
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments			0
0.	(Schedule DA)			0
6.	Contract loans			0
7.	Derivatives (Schedule DB)			0
8.	Other invested assets (Schedule BA)			0
9.	Receivables for securities			0
10.	Securities lending reinvested collateral assets (Schedule DL)			0
11.	Aggregate write-ins for invested assets	0	0	0
12.	Subtotals, cash and invested assets (Lines 1 to 11)	0	0	0
13.	Title plants (for Title insurers only)			0
14.	Investment income due and accrued	0	0	0
15.	Premiums and considerations:			
	15.1 Uncollected premiums and agents' balances in the course of collection	0	0	0
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			0
	15.3 Accrued retrospective premiums and contracts subject to redetermination			0
16.	Reinsurance:			
	16.1 Amounts recoverable from reinsurers			0
	16.2 Funds held by or deposited with reinsured companies			0
	16.3 Other amounts receivable under reinsurance contracts			0
17.	Amounts receivable relating to uninsured plans			
	Current federal and foreign income tax recoverable and interest thereon			
	Net deferred tax asset			
19.	Guaranty funds receivable or on deposit			
20.	Electronic data processing equipment and software			
20.	Furniture and equipment, including health care delivery assets			
21.	Net adjustment in assets and liabilities due to foreign exchange rates			
	Receivable from parent, subsidiaries and affiliates			
23.	Health care and other amounts receivable			
24.				
25. 26	Aggregate write-ins for other than invested assets		07 , 340	
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)			(3,297,739
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			0
28.	Total (Lines 26 and 27)	14, 187, 726	10,889,987	(3,297,739
	DETAILS OF WRITE-INS			
1101.				
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501.	Prepaid Expenses			
2502.	· ·		· · · · · · · · · · · · · · · · · · ·	
2503.				
2598.	Summary of remaining write-ins for Line 25 from overflow page			
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	42,059	67,348	25,289

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

		Total Members at End of						
		1 2 3 4 5					Current Year	
-	Source of Enrollment	Prior Year	First Quarter	Second Quarter	Third Quarter	Current Year	Member Months	
1.	Health Maintenance Organizations						4,869,966	
2.	Provider Service Organizations							
3.	Preferred Provider Organizations							
4.	Point of Service							
5.	Indemnity Only							
6.	Aggregate write-ins for other lines of business	0	0	0	0	0	0	
7.	Total	384,154	380,926	398,049	409,740	420,905	4,869,966	
	DETAILS OF WRITE-INS							
0601.								
0602.								
0603.								
0698.	Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0	
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0	

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying financial statements of AMERIGROUP Iowa, Inc. (the "Company") have been prepared in conformity with the National Association of Insurance Commissioners' ("NAIC") *Annual Statement Instructions* and in accordance with accounting practices prescribed by the NAIC *Accounting Practices and Procedures Manual* ("NAIC SAP"), subject to any deviations prescribed or permitted by the Iowa Insurance Division ("IID").

A reconciliation of the Company's net income (loss) and capital and surplus between NAIC SAP and practices prescribed and permitted by the IID is shown below:

		SSAP #	F/S Page	F/S Line #	2020	2019
Net	Income					
(1)	AMERIGROUP Iowa, Inc. state basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$188,387,801	\$ 81,828,108
(2)	State Prescribed Practices that is an increase/(decrease) from NAIC SAP:					
(3)	State Permitted Practices that is an increase/(decrease) from NAIC SAP:					
(4)	NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$188,387,801	\$ 81,828,108
<u>Sur</u>	plus					
(5)	AMERIGROUP Iowa, Inc. state basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$494,588,845	\$ 308,897,710
(6)	State Prescribed Practices that is an increase/(decrease) from NAIC SAP:					
(7)	State Permitted Practices that is an increase/(decrease) from NAIC SAP:					
(8)	NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$494,588,845	\$ 308,897,710

B. Use of Estimates in the Preparation of the Financial Statements

Preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

C. Accounting Policies

Health premiums are earned over the term of the related insurance policies. Premiums written are reported net of experience rating refunds. Premiums paid prior to the effective date are recorded on the balance sheet as premiums received in advance and are subsequently credited to income as earned during the coverage period. Premium rates are

subject to approval by the Centers for Medicare and Medicaid Services. Expenses are charged to operations as incurred.

In addition, the Company uses the following accounting policies:

- (1) Short-term investments include investments with maturities of less than one year and more than three months at the date of acquisition and are reported at amortized cost, which approximates fair value. Non-investment grade short-term investments are stated at the lower of amortized cost or fair value.
- (2) Investment grade bonds not backed by other loans are stated at amortized cost, with amortization calculated based on the modified scientific method, using lower of yield to call or yield to maturity. Non-investment grade bonds are stated at the lower of amortized cost or fair value as determined by various third-party pricing sources.

The Company holds 15 SVO-Identified bond exchange traded funds ("ETFs") reported as bonds on Schedule D-1 in which the Company has made an irrevocable decision to report at systematic value. Systematic valuation has been consistently applied to these ETFs held at December 31, 2020 and previous periods.

- (3) The Company has no investments in common stocks of unaffiliated companies.
- (4) The Company has no investments in preferred stocks.
- (5) The Company has no mortgage loans real estate.
- (6) Loan-backed securities are stated at amortized cost. Prepayment assumptions for loan-backed securities and structured securities were obtained from broker-dealer survey values or internal estimates. These assumptions are consistent with the current interest rate and economic environment. The retrospective adjustment method is used to value all loan-backed securities. Non-investment grade loan-backed securities are stated at the lower of amortized cost or fair value.
- (7) The Company has no investments in subsidiaries, controlled and affiliated companies.
- (8) The Company has no investments in joint ventures, partnerships or limited liability companies.
- (9) The Company has no derivative instruments.
- (10) The Company recognizes losses from other-than-temporary impairments ("OTTI") of investments in accordance with Statements of Standard Accounting Practice ("SSAP") No. 26R, *Bonds*; and SSAP No. 30, *Common Stock*; and SSAP No. 32, *Preferred Stock*.
- (11) The Company does not anticipate investment income as a factor in premium deficiency calculations.
- (12) Unpaid claims and claims adjustment expenses include management's best estimate of amounts based on historical claim development patterns and certain individual case estimates. The established liability considers health benefit provisions, business practices, economic conditions and other factors that may materially affect the cost, frequency and severity of claims. Liabilities for unpaid claims and claim adjustment expenses are based on assumptions and estimates, and while management believes such estimates are reasonable, the ultimate liability may be in excess of or less than the amount provided. The methods for making such estimates and for establishing the resulting liabilities are continually reviewed and changes in estimates are incorporated into current period estimates.
- (13) The Company has not modified its capitalization policy from the prior period.
- (14) Pharmacy rebate receivables are recorded when earned based upon actual rebate receivables billed and an estimate of receivables based upon current utilization of specific pharmaceuticals and provider contract terms.

D. Going Concern

Not applicable.

2. Accounting Changes and Corrections of Errors

There were no accounting changes or corrections of errors during the years ended December 31, 2020 and 2019.

3. Business Combinations and Goodwill

A. Statutory Purchase Method	Not applicable.
B. Statutory Merger	Not applicable.
C. Assumption Reinsurance	Not applicable.

D. Impairment Loss

Not applicable.

4. Discontinued Operations

The Company had no operations that were discontinued during 2020 or 2019.

5. Investments

A. Mortgage Loans, including Mezzanine Real Estate Loans

The Company did not have investments in mortgage loans at December 31, 2020 or 2019.

B. Debt Restructuring

The Company did not have invested assets that were restructured debt at December 31, 2020 or 2019.

C. Reverse Mortgages

The Company did not have investments in reverse mortgages at December 31, 2020 or 2019.

D. Loan-Backed Securities

- (1) Prepayment assumptions for single-class and multi-class mortgage-backed and assetbacked securities were obtained from broker-dealer survey values or internal estimates. The Company used various third-party pricing sources in determining the market value of its loan-backed securities.
- (2) The Company did not recognize OTTI on its loan-backed securities during the years ended December 31, 2020 and 2019.
- (3) The Company did not recognize OTTI on its loan-backed securities at December 31, 2020 and 2019.
- (4) All impaired securities (fair value is less than cost or amortized cost) for which an other-than-temporary impairment has not been recognized in earnings as a realized loss (including securities with a recognized other-than-temporary impairment for noninterest related declines when a non-recognized interest related impairment remains):

a.	The aggregate amount of unrealized losses:			
		1.	Less than 12 Months	\$ (212,927)
		2.	12 Months or Longer	\$ —
b.	The aggregate related fair value of securities with unrealized losses:			
		1.	Less than 12 Months	\$ 12,335,369
		2.	12 Months or Longer	\$ _

(5) The Company's bond portfolio is sensitive to interest rate fluctuations, which impact the fair value of individual securities. Unrealized losses on bonds were primarily caused by the effects of the interest rate environment and the widening of credit spreads on certain securities. The Company currently has the ability and intent to hold

these securities until their full cost can be recovered. Therefore, the Company does not believe the unrealized losses represent an OTTI at December 31, 2020 or 2019.

E. Dollar Repurchase Agreements and/or Securities Lending Transactions

- (1) The Company did not enter into repurchase agreements at December 31, 2020 or 2019.
- (2) The Company participates in a securities lending program whereby marketable securities in its investment portfolio are transferred to independent brokers or dealers based on, among other things, their creditworthiness in exchange for collateral initially equal to at least 102% of the market value of the loaned securities. The Company receives the collateral in cash or securities, and if cash is received the cash collateral is thereafter invested according to guidelines of the Company's Investment Policy.
- (3) Collateral Received

1.

a. Aggregate amount collateral received

		<u>Fair Val</u>			
Secu	rities Lending				
(a)	Open	\$	32,477,920		
(b)	30 days or less				
(c)	31 to 60 days				
(d)	61 to 90 days				
(e)	Greater than 90 days				
(f)	Sub-total		32,477,920		
(g)	Securities received		3,511,369		
(h)	Total collateral received	\$	35,989,289		

2. Dollar repurchase agreement - Not applicable.

- b. The fair value of that collateral and of the portion of that collateral that it has sold or repledged \$35,989,289\$
- c. The Company receives cash collateral in an amount in excess of fair value of the securities lent. The Company reinvests the cash collateral according to guidelines of the Company's Investment Policy.
- (4) The Company does not have any securities lending transactions administered by an affiliated agent.

(5) Collateral Reinvestment

a. Aggregate amount collateral reinvested

			Amortized Cost			<u>Fair Value</u>
1.	Secu	rities Lending				
	(a)	Open	\$	_	\$	_
	(b)	30 days or less		16,940,609		16,940,967
	(c)	31 to 60 days		8,402,736		8,402,715
	(d)	61 to 90 days		4,859,214		4,858,554
	(e)	91 to 120 days		—		
	(f)	121 to 180 days		552,787		553,067
	(g)	181 to 365 days		1,722,357		1,722,617
	(h)	1 to 2 years				
	(i)	2 to 3 years		—		
	(j)	Greater than 3 years				
	(k)	Sub-total	\$	32,477,703	\$	32,477,920
	(1)	Securities received		3,511,369		3,511,369
	(m)	Total collateral reinvested	\$	35,989,072	\$	35,989,289

- 2. Dollar repurchase agreement Not applicable.
- b. Not applicable.
- (6) Not applicable.
- (7) Not applicable.

F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

The Company did not enter into repurchase agreement transactions accounted for as secured borrowing at December 31, 2020 or 2019.

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

The Company did not enter into reverse repurchase agreement transactions accounted for as a secured borrowing at December 31, 2020 or 2019.

H. Repurchase Agreements Transactions Accounted for as a Sale

The Company did not enter into repurchase agreement transactions accounted for as a sale at December 31, 2020 or 2019.

I. Reverse Repurchase Agreements Transactions Accounted for as a Sale

The Company did not enter into reverse repurchase agreement transactions accounted for as a sale at December 31, 2020 or 2019.

J. Real Estate

The Company did not have investments in real estate and did not engage in retail land sales operations during 2020 or 2019.

K. Investments in Low-Income Housing Tax Credits

The Company did not invest in properties generating low-income housing tax credits during 2020 or 2019.

L. Restricted Assets

(1) Restricted assets (including pledged)

		1	2	3	4	5	6	7
Res	stricted Asset Category	Total Gross (Admitted & Nonadmitted) Restricted from Current Year	Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	Increase/ (Decrease) (1 minus 2)	Total Current Year Nonadmitted Restricted	Total Current Year Admitted Restricted (1 minus 4)	Gross Admitted and Nonadmitted Restricted to Total Assets (a)	Admitted Restricted to Total Admitted Assets (b)
a.	Subject to contractual obligation for which liability is not shown	s —	s —	s —	s —	s —	0.00 %	0.00 %
b.	Collateral held under security lending agreements	35,989,072	2,409,425	33,579,647	<u> </u>	35,989,072	4.04 %	4.11 %
c.	Subject to repurchase agreements				_	_	0.00 %	0.00 %
d.	Subject to reverse repurchase agreements	_					0.00 %	0.00 %
e.	Subject to dollar repurchase agreements	_		_	_		0.00 %	0.00 %
f.	Subject to dollar reverse repurchase agreements	_			_	_	0.00 %	0.00 %
g.	Placed under option contracts				_	_	0.00 %	0.00 %
h.	Letter stock or securities restricted as to sale-excluding FHLB capital stock	_	_	_	_	_	0.00 %	0.00 %
i.	FHLB capital stock						0.00 %	0.00 %
j.	On deposit with states	—			_		0.00 %	0.00 %
k.	On deposit with other regulatory bodies				_		0.00 %	0.00 %
1.	Pledged as collateral to FHLB (including assets backing funding agreements)						0.00 %	0.00 %
m.	Pledged as collateral not captured in other categories						0.00 %	0.00 %
n.	Other restricted assets				_	_	0.00 %	
0.	Total Restricted Assets	\$35,989,072	\$ 2,409,425	\$33,579,647	\$ —	\$35,989,072	4.04 %	4.11 %

(a) Column 1 divided by Asset Page, Column 1, Line 28(b) Column 5 divided by Asset Page, Column 3, Line 28

(2) Not applicable.


(3) Not applicable.

		1	2	3	4
	Collateral Assets	Book/Adjusted Carrying Value (BACV)	Fair Value	% of BACV to Total Assets (Admitted and Nonadmitted*)	% of BACV to Total Admitted Assets **
a.	Cash	\$ —	\$ —	— %	- %
b.	Schedule D, Part 1				_
c.	Schedule D, Part 2 Section 1			_	_
d.	Schedule D, Part 2 Section 2				_
e.	Schedule B				_
f.	Schedule A	—	—	_	—
g.	Schedule BA, Part 1	—	—	_	_
h.	Schedule DL, Part 1	35,989,072	35,989,289	4.04 %	4.11 %
i.	Other	_	_	_	
j.	Total Collateral Assets (a+b+c+d+e+f+g+h+i)	\$ 35,989,072	\$ 35,989,289	4.04 %	4.11 %

(4) Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements

* Column 1 divided by Asset Page, Line 26 (Column 1)

** Column 1 divided by Asset Page, Line 26 (Column 3)



* Column 1 divided by Liability Page, Line 24 (Column 3)

M. Working Capital Finance Investments

The Company did not have any working capital finance investments at December 31, 2020 and 2019.

N. Offsetting and Netting of Assets and Liabilities

The Company did not have any offsetting or netting of assets and liabilities at December 31, 2020 and 2019.

O. 5GI Securities

The Company has no 5GI Securities as of December 31, 2020 and 2019.

P. Short Sales

The Company did not have any short sales at December 31, 2020 and 2019.

Q. Prepayment Penalty and Acceleration Fees

			General Account		
(1)	Number of CUSIPs		2		
(2)	Aggregate Amount of Investment Income	e \$	55,716		

6. Joint Ventures, Partnerships and Limited Liability Companies

- A. The Company has no investments in joint ventures, partnerships or LLCs.
- **B.** Not applicable

7. Investment Income

- A. All investment income due and accrued with amounts that are over 90 days past due is non-admitted.
- **B.** At December 31, 2020 and 2019 there was no nonadmitted accrued investment income.

8. Derivative Instruments

The Company has no derivative instruments.

9. Income Taxes

A. The components of net deferred tax assets (liabilities):

(1) The components of net deferred tax asset (liabilities) are as follows:

		12/31/2020					
			(1)		(2)		(3)
			Ordinary		Capital	((Col 1+2) Total
(a)	Gross Deferred Tax Assets	\$	5,392,767	\$	_	\$	5,392,767
(b)	Statutory Valuation Allowance Adjustments		_		_		
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)		5,392,767		_		5,392,767
(d)	Deferred Tax Assets Nonadmitted		184,864		_		184,864
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)		5,207,903		_		5,207,903
(f)	Deferred Tax Liabilities		8,083		142,994		151,077
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$	5,199,820	\$	(142,994)	\$	5,056,826

		12/31/2019					
			(4)		(5)		(6)
			Ordinary		Capital	(Col 4+5) Total
(a)	Gross Deferred Tax Assets	\$	4,668,369	\$	_	\$	4,668,369
(b)	Statutory Valuation Allowance Adjustments		_		_		
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)		4,668,369		_		4,668,369
(d)	Deferred Tax Assets Nonadmitted		346,584		—		346,584
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)		4,321,785		_		4,321,785
(f)	Deferred Tax Liabilities		7,237		13,606		20,843
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$	4,314,548	\$	(13,606)	\$	4,300,942

Change

		(7)		(7) (8)		(9)
		(Col 1-4) Ordinary		Col 2-5) Capital	(Col 7+8) Total
(a)	Gross Deferred Tax Assets	\$ 724,398	\$	_	\$	724,398
(b)	Statutory Valuation Allowance Adjustments	 		_		
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)	724,398		_		724,398
(d)	Deferred Tax Assets Nonadmitted	 (161,720)		_		(161,720)
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	886,118		_		886,118
(f)	Deferred Tax Liabilities	 846		129,388		130,234
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$ 885,272	\$	(129,388)	\$	755,884

(2) The amount of admitted adjusted gross deferred tax assets under each component of SSAP No. 101, *Income Taxes* ("SSAP No. 101") are as follows:

(1)(2)(3)(3)(Ca I + 2)Admission Calculation Components SSAP No. 101(a)Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.\$ 5,036,829 \$ - \$ 5,036,829(b)Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) Aflusted Gross Deferred Tax Assets Allowed per Limitation Threshold.19,997 - 19,9971.Adjusted Gross Deferred Tax Assets Clocking The Amount Of Deferred Tax Assets Clocking The Amount Of Deferred Tax Assets Clocking The Amount Of Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))5 5,207,903 \$ - \$ 5,207,903(a)Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.5 4,270,200 \$ - \$ 4,270,200(b)Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.5 4,270,200 \$ - \$ 4,270,200(a)Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.5 4,270,200 \$ - \$ 4,270,200(b)Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.5 3,742 - 30,742(c)Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.3 3,742 - 30,742(c)Adjusted Gross Deferred Tax Assets Scie From 2(a) above) After Application of the Threshold Limitation. Threshold.5 4,221,785 \$ - \$ 4,321,785(c)Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.5			12/31/2020				
OrdinaryCapitalTotalAdmission Calculation Components SSAP No. 101(a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carybacks.(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)) and 2(b) above) Offset by Gross Deferred Tax Assets Admitted as the result of application of SSAP No. 101(c) S (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))(c) Adjusted Gross Deferred Tax Assets Capital(c) Adjusted Gross Deferred Tax Assets Expected To Be (c) above) Adjusted Gross Deferred Tax Assets Expected To application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))(c) Adjusted Gross Deferred Tax Assets Capital(c) Adjusted Gross Deferred Tax Assets Expected To Be (c) Adjusted Gross Deferred Tax Assets Expected To Be Realized (C) Adjusted Gross Deferred Tax Assets Expected To Be Realized (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.(c) Adjusted Gross Deferred Tax Assets Expected To Be (c) Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.(c) Adjusted Gross Deferred Tax Assets Expected To Be (c) Adjusted G			(1)	(2)	(3)		
(a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.55,036,829 $-$ \$5,036,829(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.19,997 $-$ 19,9971. Adjusted Gross Deferred Tax Assets Supected To Be Realized Following the Balance Sheet Date.19,997 $-$ 19,9972. Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)) $xxx x xxx xxx 73,429,803$ (d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)) $xxx x xxx xxx 73,429,803$ (e) Adjusted Gross Deferred Tax Assets Expected To Be Realized Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Loss Carrybacks. $x = 5,207,903 \ s = - \ s - 5,207,903$ (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. $x = 30,742 \ 30,7$			Ordinary	Capital			
Loss Carrybacks. $\$$ 5,036,829 $\$$ - $\$$ 5,036,829 (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. 19,997 - 19,997 1. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. The assets Allowed per Limitation Threshold Limitation (The Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Labilities. (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)) (a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets Form 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) 1. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. 2. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. 2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. (c) Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold Limitation. (The Lesser of 2(b)1 and 2(b) 2 below) 1. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. (c) Adjusted Gross Deferred Tax Assets Kuluded per Limitation Threshold. (b) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Libbilities. (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred	Adr	nission Calculation Components SSAP No. 101	· · · · ·				
Loss Carrybacks. (5 5,036,829 S - S 5,036,829 (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. 19,997 - 19,997 1. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. (2) (2) Below) (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)) (d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)) (e) Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. (f) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)) (a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) 1. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. 2. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. 2. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. 2. Adjusted Gross Deferred Tax Assets Laylowed per Limitation Threshold. (c) Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets From 2(a) and 2(b) above) Offset b	(a)						
(Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)19,997-19,9971. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.19,997-19,9972. Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Labilities.19,997-19,997(c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Labilities.XXXXXX73,429,803(d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))55,207,903\$-\$5,207,903(d) Deferred Tax Assets Paid in Prior Years Recoverable Through Loss Carrybacks.54,270,200\$-\$4,270,200(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.54,270,200\$-\$4,270,200(a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.\$4,270,200\$-\$4,270,200(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.30,742-30,742-30,742(c) Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.1030,742-30,742-30,742(c) Adjusted Gross Deferred Tax Assets Stepected To Be Realized Following the Balance Sheet Date.30,742-30,742-30,742(c) Adjusted Gross		Loss Carrybacks.	\$ 5,036,829	\$ —	\$ 5,036,829		
1. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.19,997.2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. $19,997$ (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Liabilities. $13,097$ (d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total $(2(a) + 2(b) + 2(c))$ $151,077$ (a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. $5,207,903$ \$.\$(a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. $8, 4,270,200$ \$.\$4,270,200(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) $30,742$. $30,742$. $30,742$.(c) Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.The Amount Of Deferred Tax Assets Allowed per Limitation Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) $30,742$. $30,742$. $30,742$.(c) Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.The Amount Of Deferred Tax Assets Allowed per Limitation Threshold. $30,742$ $30,742$. $30,742$ (d) Deferred Tax Assets Form 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Admitted as the result of application of <td>(b)</td> <td>(Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The</td> <td>10.007</td> <td></td> <td>10.007</td>	(b)	(Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The	10.007		10.007		
Realized Following the Balance Sheet Date.19,997-19,9972. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. XXX XXX XXX $73,429,803$ (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)) XXX XXX XXX $73,429,803$ (d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)) $5,207,903$ $5,-8$ $5,207,903$ (a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. $5,4,270,200$ $5,-8$ $4,270,200$ (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. $30,742$ $ 30,742$ 2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. $30,742$ $ 30,742$ $-$ (c) Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. XXX XXX $45,689,515$ (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets Form 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Form 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Form 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Form 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Form 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Form 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Form 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Form 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Form 2(a) and 2(b) above) Offset by G			19,997		19,997		
Threshold.XXXXXX73,429,803(c)Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Liabilities. $151,077$ $ 151,077$ (d)Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)) $5,207,903$ $ 5,207,903$ (d)Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)) $5,207,903$ $ 5,207,903$ (a)Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. $5,4,270,200$ $ 5,4,270,200$ (a)Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. $5,4,270,200$ $ 5,4,270,200$ (b)Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) $30,742$ $ 30,742$ 1.Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. $30,742$ $ 30,742$ $ 30,742$ (c)Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Admitted as the result of application of $20,843$ $ 20,843$		Realized Following the Balance Sheet Date.	19,997	_	19,997		
Indicate the function of the func		2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.	XXX	XXX	73,429,803		
SSAP No. 101. Total $(2(a) + 2(b) + 2(c))$ SSAP No. 101. Total $(2(a) + 2(b) + 2(c))$ SSAP No. 101. Total $(2(a) + 2(b) + 2(c))$ Admission Calculation Components SSAP No. 101 (a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) 1. Adjusted Gross Deferred Tax Assets Streeted To Be Realized Following the Balance Sheet Date. 2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets Admitted as the result of application of	(c)	Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross		_	151,077		
(4)(5)(6)OrdinaryCapital(Col 4+5)OrdinaryCapitalTotalAdmission Calculation Components SSAP No. 101(a)Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.\$ 4,270,200 \$ - \$ 4,270,200(b)Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)30,742 - 30,7421.Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.30,742 - 30,7422.Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.30,742 - 30,742(c)Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Admitted as the result of application of20,843 - 20,843	(d)	Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total $(2(a) + 2(b) + 2(c))$	\$ 5,207,903	\$ —	\$ 5,207,903		
(4)(5)(6)OrdinaryCapital(Col 4+5)Admission Calculation Components SSAP No. 101(a)Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.\$ 4,270,200 \$ - \$ 4,270,200(b)Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)\$ 30,742 - \$ 30,7421.Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.\$ 30,742 - \$ 30,7422.Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.\$ XXX X XX 45,689,515(c)Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Admitted as the result of application of\$ 20,843 - \$ 20,843							
OrdinaryCapital(Col 4+5) TotalAdmission Calculation Components SSAP No. 101(a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.\$ 4,270,200 \$ - \$ 4,270,200(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)30,742 - 30,7421. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.30,742 - 30,7422. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.XXX X XX 45,689,515(c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Admitted as the result of application of20,843 - 20,843							
OrdinaryCapitalTotalAdmission Calculation Components SSAP No. 101(a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.\$ 4,270,200 \$ \$ 4,270,200(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)30,742 30,7421. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.30,742 30,7422. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.XXX X XXX 45,689,515(c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.20,843 20,843(d) Deferred Tax Assets Admitted as the result of application of				12/31/2019			
 (a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) 1. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. 2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets Ker Prom 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Admitted as the result of application of 			(4)		(6)		
Loss Carrybacks.\$ 4,270,200 \$ \$ 4,270,200(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)30,742				(5)	(Col 4+5)		
 (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) 30,742 — 30,742 Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Admitted as the result of application of 	Adr	nission Calculation Components SSAP No. 101		(5)	(Col 4+5)		
Lesser of 2(b)1 and 2(b)2 Below)30,74230,7421. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.30,74230,7422. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.30,74230,742(c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Assets Admitted as the result of application of20,84320,843		Federal Income Taxes Paid in Prior Years Recoverable Through	Ordinary	(5) Capital	(Col 4+5) Total		
Realized Following the Balance Sheet Date. 30,742 — 30,742 2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. XXX XXX 45,689,515 (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities. 20,843 — 20,843 (d) Deferred Tax Assets Admitted as the result of application of — 20,843 — 20,843	(a)	Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a)	Ordinary	(5) Capital	(Col 4+5) Total		
Threshold.XXXXXX45,689,515(c)Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.20,843—20,843(d)Deferred Tax Assets Admitted as the result of application of20,843—20,843	(a)	Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)	Ordinary \$ 4,270,200	(5) Capital	(Col 4+5) Total \$ 4,270,200		
Majarter Gross Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities. 20,843 — 20,843 (d) Deferred Tax Assets Admitted as the result of application of — 20,843 — 20,843	(a)	 Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) Adjusted Gross Deferred Tax Assets Expected To Be 	Ordinary \$ 4,270,200 30,742	(5) Capital	(Col 4+5) Total \$ 4,270,200 30,742		
C > Deferred Tax risses riamated as the result of appreadon of	(a)	 Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. Adjusted Gross Deferred Tax Assets Allowed per Limitation 	Ordinary \$ 4,270,200 30,742 30,742	(5) Capital \$ —	(Col 4+5) Total \$ 4,270,200 30,742 30,742		
	(a) (b)	 Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross 	Ordinary \$ 4,270,200 30,742 30,742 XXX	(5) Capital \$ —	(Col 4+5) Total \$ 4,270,200 30,742 30,742 45,689,515		

(Col 1-4)(Col 2-5)(Col 2-5)OrdinaryCapitalTot	/
Admission Calculation Components SSAP No. 101	
 (a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. \$ 766,629 \$ \$ 76 	56,629
 (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) (10,745) — (10,745) 	0,745)
1. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.(10,745)(10,745)	0,745)
2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold. XXX XXX 32,49	95,792
 (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities. 130,234 — 130,234	30,234
(d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c)) <u>\$ 886,118 \$ - \$ 88</u>	36,118

Change

(3)					2020		2019
	(a) Ratio Percentage Use Threshold Limitation		e Recovery Pe	riod And	2	426 %	346 %
	(b) Amount Of Adjusted Determine Recovery 2(b)2 Above.				484,532,0	019 \$	304,596,768
(4)		12/31	/2020	12/3	1/2019	Ch	ange
		(1)	(2)	(3)	(4)	(5)	(6)
		Ordinary	Capital	Ordinary	Capital	(Col 1-3) Ordinary	(Col 2-4) Capital
	act of Tax-Planning tegies		-				
(a)	Determination of Adjusted Gross Deferred Tax Assets and Net Admitted Deferred Tax Assets, By Tax Character As A Percentage.						
	 Adjusted Gross DTAs Amount From Note 9A1(c) 	\$ 5,392,767	\$ —	\$ 4,668,369	\$ —	\$ 724,398	\$ —
	2. Percentage of Adjusted Gross DTAs By Tax Character Attributable To The Impact Of Tax Planning Strategies	0.00 %	6 0.00 %	0.00	% 0.00 %	% 0.00	% 0.00 %
	3. Adjusted Gross DTAs Amount From Note 9A1(e)	\$ 5,207,903	\$ —	\$ 4,321,785	\$ —	\$ 886,118	\$ —
	4. Percentage of Net Admitted Adjusted Gross DTAs By Tax Character Admitted Because Of The Impact Of Tax Planning Strategies	0.00 %					
(b)	Does the Company's tax- the use of reinsurance?	planning strategi	es include	Ye	·S	N	0 <u>X</u>

B. The Company has no unrecognized deferred tax liabilities at December 31, 2020 and 2019.

C. Current income taxes incurred consist of the following major components:

				(1)		(2)		(3)
				1	2/31/2020	12/31/2019		(Col 1-2) Change
(1)	Cur	rent Ind	come Tax					
	(a)	Feder	al	\$	59,575,027	\$ 22,130,960	\$	37,444,067
	(b)	Foreig	gn			_		
	(c)	Subto	tal		59,575,027	22,130,960		37,444,067
	(d)	Feder	al income tax expense on net capital gains		546,495	367,845		178,650
	(e)	Utiliz	ation of capital loss carry-forwards		_	_		—
	(f)	Other				_		
	(g)	Feder	al and foreign income taxes incurred	\$	60,121,522	\$ 22,498,805	\$	37,622,717
(2)			'ax Assets:					
	(a)	Ordin	ary					
		(1)	Discounting of unpaid losses	\$	1,091,987	\$ 782,032	\$	309,955
		(2)	Unearned premium reserve		19,610	16,405		3,205
		(3)	Policyholder reserves		1,722,879	2,076,582		(353,703)
		(4)	Investments		—	—		—

	(5)	Deferred acquisition costs	_	—	—
	(6)	Policyholder dividends accrual	—	—	—
	(7)	Fixed assets	392,926	411,749	(18,823)
	(8)	Compensation and benefits accrual	—	—	
	(9)	Pension accrual	—	—	
	(10)	Receivables - nonadmitted	2,151,263	1,314,136	837,127
	(11)	Net operating loss carry-forward	—	—	
	(12)	Tax credit carry-forward	—	—	
	(13)	Other (including items <5% of total ordinary tax assets)	14,102	53,115	(39,013)
	(14)	Accrued future expenses			(39,013)
	(15)	Amortization		_	_
	(16)	Partnership income			
	(17)	Premium deficiency reserves		_	
	(18)	Prepaid expenses		14,350	(14,350)
	(19)	Section 467 lease expense			(11,550)
	(1) (20)	Personal property tax accrual		_	_
	(20)	Deferred gain on sale of building		_	_
	(21) (22)	State income tax liability		_	_
	(22)	Income from reinsurance contract			
	(23)	Revenue agent's report adjustment			
	(24)	(99) Subtotal	5,392,767	4,668,369	724,398
(b)	Statu	tory valuation allowance adjustment	5,592,707	4,008,509	724,598
(0) (c)		dmitted	184,864	346,584	(161,720)
(c) (d)		itted ordinary deferred tax assets (2a99 - 2b - 2c)	5,207,903	4,321,785	886,118
(u) (e)	Capit		5,207,905	4,521,765	000,110
(e)	-	Investments			
	(1) (2)	Net capital loss carry-forward		—	
		Real estate		—	
	(3) (4)	Other (including items $<5\%$ of total capital tax		—	
	(1)	assets)		_	
	(5)	Partnership investment		_	
	(6)	State low income housing tax credits	_	_	
	(7)	Affiliated investment write-down			
		(99) Subtotal			
(f)	Statu	tory valuation allowance adjustment	_	_	
(g)	Nona	dmitted	_	_	
(h)	Admi	itted capital deferred tax assets (2e99 - 2f - 2g)	_	_	
(i)	Admi	itted deferred tax assets (2d + 2h)	\$ 5,207,903	\$ 4,321,785	\$ 886,118
			(1)	(2)	(3)
			12/31/2020	12/31/2019	(Col 1-2) Change
Def	Perrod 7	ſax Liabilities:	12/31/2020	12/31/2019	Change
(a)	Ordin				
(a)	(1)	Investments	\$ —	\$	\$
	(1) (2)	Fixed assets	φ	ψ	φ
	(2)	Deferred and uncollected premium			
	(3)	Policyholder reserves		—	
	(4)	Other (including items <5% of total ordinary		—	
	(0)	tax liabilities)	_		
	(6)	Amortization		_	
	(7)	Discount of coordination of benefits	8,083	7,237	846
	(8)	Guaranty fund assessment	_	_	_
	(9)	Business partnership	_	_	
	(10)	Tax reserves per Tax Reform over 8 years	_	_	_
	(11)	Oil and gas depletion deduction		_	
	(12)	Deferred cost - surplus note			
		(99) Subtotal	8,083	7,237	846
(b)	Capit	al			

(3)

(1)	Investments	142,994	13,606	129,388
(2)	Real estate		_	_
(3)	Other (including items <5% of total capital tax liabilities)	_	_	_
(4)	Section 166 partial worthlessness	_	—	
(5)	Investment partnership income	 	—	—
	(99) Subtotal	142,994	13,606	129,388
(c) Defe	rred tax liabilities (3a99 + 3b99)	\$ 151,077 \$	20,843	\$ 130,234
(4) Net deferr	ed tax assets/liabilities (2i - 3c)	\$ 5,056,826 \$	4,300,942	\$ 755,884

D. The Company's income tax expense and change in deferred income taxes differs from the amount obtained by applying the federal statutory income tax rate of 21% for the year ended December 31 as follows:

	2020	2019
Tax expense computed using federal statutory rate	\$ 52,186,958	\$ 21,908,652
ACA health insurer fee	8,066,495	_
Change in nonadmitted assets	(726,486)	231,096
Tax exempt income and dividend received deduction net of proration	(253,283)	(81,545)
Prior year true-up and adjustments	174,066	469,285
Tax settlements and contingencies	—	(801,393)
Valuation allowance	—	(483,451)
Other, net	78,158	(342,210)
Total	\$ 59,525,908	\$ 20,900,434
Federal income taxes incurred	\$ 60,121,523	\$ 22,498,805
Change in net deferred income taxes	(595,615)	(1,598,371)
Total statutory income taxes	\$ 59,525,908	\$ 20,900,434

E. Operating loss carryforwards:

- (1) The Company has no operating loss carryforwards and no tax credit carryforwards as of December 31, 2020 or 2019.
- (2) The following are income taxes incurred in the current and prior year(s) that will be available for recoupment in the event of future net losses:

	 Ordinary	Capital	Total
2020	\$ 59,984,443 \$	546,495 \$	60,530,938
2019	22,591,335	367,845	22,959,180
2018	N/A		—

- (3) The Company has no protective tax deposits reported as admitted assets under Section 6603 of the Internal Revenue Service Code as of December 31, 2020 and 2019.
- **F.** The following companies will be included in the consolidated federal income tax return with their parent Anthem, Inc. ("Anthem") as of December 31, 2020 and either are current members of the consolidated tax sharing agreement or are in the process of being added to the consolidated tax sharing agreement. Allocation of federal income taxes with affiliates subject to the tax sharing agreement is based upon separate income tax return calculations with credit for net losses that can be used on a consolidated basis. Pursuant to this agreement, the Company has the enforceable right to recoup federal income taxes paid in prior years in the event of future losses, which it may incur, or to recoup its net losses carried forward as an offset to future net income subject to federal income taxes.

Intercompany income tax balances are settled based on the Internal Revenue Service due dates.

American Imaging Management, Inc. America's 1st Choice of South Carolina, Inc. America's Health Management Services, Inc. AMERIGROUP Community Care of New Mexico, Inc. AMERIGROUP Corporation Amerigroup Delaware, Inc. AMERIGROUP District of Columbia, Inc. Amerigroup Health Plan of Louisiana, Inc. Amerigroup Insurance Company AMERIGROUP Iowa, Inc. Amerigroup Kansas, Inc. AMERIGROUP Maryland, Inc. AMERIGROUP Mississippi, Inc. AMERIGROUP New Jersey, Inc. AMERIGROUP Ohio, Inc. AMERIGROUP Oklahoma, Inc. Amerigroup Pennsylvania, Inc. AMERIGROUP Tennessee, Inc. AMERIGROUP Texas Inc. AMERIGROUP Washington, Inc. AMGP Georgia Managed Care Company, Inc. Anthem Blue Cross Life and Health Insurance Company Anthem Financial, Inc. Anthem Health Plans of Kentucky, Inc. Anthem Health Plans of Maine, Inc. Anthem Health Plans of New Hampshire, Inc. Anthem Health Plans of Virginia, Inc. Anthem Health Plans, Inc. Anthem Holding Corp. Anthem Insurance Companies, Inc. Anthem Kentucky Managed Care Plan, Inc. Anthem Southeast, Inc. Anthem UM Services, Inc. Anthem, Inc. Arcus Enterprises, Inc. Aspire Health, Inc. Associated Group, Inc. Beacon Health Financing, LLC Beacon Health Options Care Services, Inc. Beacon Health Options Holdco, Inc. Beacon Health Options, Inc. Beacon Health Options of California, Inc. Beacon Health Options of Ohio, Inc. Beacon Health Options of Pennsylvania, Inc. Beacon Health Vista Parent, Inc. BHS IPA, LLC Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Blue Cross Blue Shield of Wisconsin Blue Cross of California Blue Cross of California Partnership Plan, Inc. CareMarket, Inc. CareMore Health Plan CareMore Health Plan of Arizona. Inc. CareMore Health Plan of Nevada, Inc. CareMore Health Plan of Texas, Inc. CareMore Health System Cerulean Companies, Inc.

Designated Agent Company, Inc. EHC Benefits Agency, Inc. Empire HealthChoice Assurance, Inc. Empire HealthChoice HMO, Inc. Federal Government Solutions, LLC FHC Health Systems, Inc. Freedom Health, Inc. Golden West Health Plan. Inc. Health Core, Inc. Health Management Corporation HealthKeepers, Inc. HealthLink HMO, Inc. HealthLink Insurance Company HealthLink, Inc. HealthPlus HP, LLC HealthSun Health Plan, Inc. Healthy Alliance Life Insurance Company HEP AP Holdings, Inc. Highland Holdco, Inc. HMO Colorado, Inc. HMO Missouri. Inc. IEC Group Holdings, Inc. IEC Group, Inc. d/b/a AmeriBen Imaging Management Holdings, LLC IngenioRx, Inc. Legato Holdings I, Inc. Living Complete Technologies, Inc. Massachusetts Behavioral Health Partnership Matthew Thornton Health Plan, Inc. Missouri Care, Incorporated Nash Holding Company, LLC National Government Services, Inc. New England Research Institutes, Inc. Optimum Healthcare, Inc. OPTIONS Health Care, Inc. Park Square Holdings, Inc. Park Square I, Inc. Park Square II, Inc. Resolution Health, Inc. RightCHOICE Managed Care, Inc. Rocky Mountain Hospital and Medical Service, Inc. SellCore. Inc. Simply Healthcare Plans, Inc. Southeast Services, Inc. State Sponsored Services. Inc. The Anthem Companies of California, Inc. The Anthem Companies, Inc. TrustSolutions, LLC UNICARE Health Plan of West Virginia, Inc. UNICARE Illinois Services. Inc. UNICARE Life & Health Insurance Company UNICARE National Services, Inc. UNICARE Specialty Services, Inc. Value Health Reinsurance, Inc. ValueOptions Federal Services, Inc. ValueOptions New Mexico, Inc. ValueOptions of Kansas, Inc.

CHCS IPA, Inc. Claim Management Services, Inc. Community Care Health Plan of Nebraska, Inc. fka WellCare of Nebraska, Inc. Community Care Health Plan of Nevada, Inc. Community Insurance Company Compcare Health Services Insurance Corporation Crossroads Acquisition Corp. DBG Holdings, Inc. DeCare Analytics, LLC DeCare Dental Health International, LLC DeCare Dental Networks, LLC DeCare Dental, LLC ValueOptions of New Jersey, Inc. ValueOptions Texas, Inc.

Valus, Inc. WellPoint California Services, Inc. WellPoint Dental Services, Inc. WellPoint Health Solutions, Inc. WellPoint Holding Corporation WellPoint Information Technology Services, Inc. WellPoint Insurance Services, Inc. WellPoint Military Care Corporation ZipDrug, Inc.

G. Not applicable.

H. Repatriation Transition Tax (RTT)

Not applicable.

I. Alternative Minimum Tax (AMT) Credit

Not applicable.

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

A. Nature of the Relationship

The Company is a Iowa domiciled stock insurance company and is a wholly-owned subsidiary of AMERIGROUP Corporation ("AGP"), which is an indirect wholly-owned subsidiary of Anthem, a publicly traded company.

B. Significant Transactions for Each Period

The following significant transactions took place between the Company and its affiliates:

The company received a capital contribution in the amount of \$55,000,000 from Anthem, Inc. on December 30, 2019.

For changes to the intercompany management and service arrangements see Note 10E. The amounts of transactions under such agreements are presented in Schedule Y, Part 2.

C. Transactions with Related Parties who are not Reported on Schedule Y

The Company has no transactions with related parties who are not reported on Schedule Y.

D. Amounts Due to or from Related Parties

At December 31, 2020 and 2019, the Company reported no amounts due from affiliates. At December 31, 2020 and 2019, the Company reported \$4,004,603 and \$11,313,693 due to affiliates, respectively. The receivable and payable balances represent intercompany transactions that will be settled in accordance with the settlement terms of the intercompany agreement.

E. Management and Service Contracts and Cost Sharing Arrangements

The Company has entered into administrative services agreements with its affiliated companies. Pursuant to these agreements, various administrative, management and support services are provided to or provided by the Company. The costs and expenses

related to these administrative management and support services are allocated to or allocated by the Company in an amount equal to the direct and indirect costs and expenses incurred in providing these services. Costs include expenses such as salaries, employee benefits, information technology, pharmacy benefits administration, communications, advertising, consulting services, rent, utilities, billing, accounting, underwriting, and product development, which support the Company's operations. These costs are allocated based on various utilization statistics.

In addition, the Company is party to the Fair Market Value ("FMV") Services Attachment, starting January 1, 2019, the costs and expenses related to certain care management and other services are allocated to or allocated by the Company in an amount equal to the fair market value of the services provided. These costs are allocated based on various utilization statistics.

During 2020, the Company added the Beacon Management Services Agreement which will provide behavioral health services. The agreement was approved on September 18, 2020 and is effective beginning January 1, 2021.

F. Guarantees or Contingencies for Related Parties

The Company did not enter into guarantees or undertakings for the benefit of an affiliate which would result in a material contingent exposure of the Company's or any affiliated insurer's assets or liabilities.

G. Nature of Control Relationships that Could Affect Operations or Financial Position

AGP owns all outstanding shares of the Company. The Company's ultimate parent is Anthem.

H. Amount Deducted for Investment in Upstream Company

The Company does not own shares of upstream intermediate entities or Anthem.

I. Detail of Investments in Affiliates Greater than 10% of Admitted Assets

At December 31, 2020 and 2019, the Company did not have investments in affiliates.

J. Write-down for Impairments of Investments in Subsidiaries, Controlled or Affiliated ("SCA") Companies

Not applicable.

K. Investment in a Foreign Insurance Subsidiary

The Company does not have investments in foreign insurance subsidiaries.

L. Investment in Downstream Non-insurance Holding Companies

The Company does not have investments in downstream non-insurance holding companies.

M. All SCA Investments

The Company has no SCA Investments.

N. Investment in Insurance SCAs

The Company does not have investments in Insurance SCAs.

O. SCA or SSAP 48 Entity Loss Tracking

The Company does not have losses on investments in Insurance SCAs and/or joint ventures, partnerships or LLCs.

11. Debt

A. Capital Notes and Other Debt

The Company had no capital notes or other debt outstanding at December 31, 2020 and 2019.

B. FHLB (Federal Home Loan Bank) Agreements

The Company had no FHLB agreements outstanding at December 31, 2020 and 2019.

C. All Other Debt

The Company had no other debt outstanding at December 31, 2020 and 2019.

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

A. Defined Benefit Plan

Not applicable - See Note 12G.

- **B.** Not applicable See Note 12G.
- **C.** Not applicable See Note 12G
- **D.** Not applicable See Note 12G.

E. Defined Contribution Plans

Not applicable - See Note 12G.

F. Multiemployer Plans

The Company does not participate in a multiemployer plan.

G. Consolidated/Holding Company Plans

The Company participates in a nonqualified deferred compensation plan sponsored by Anthem which covers certain employees once the participant reaches the maximum contribution amount for the Anthem 401(k) Plan (the "401(k) Plan"). The deferred amounts are payable according to the terms and subject to the conditions of the deferred compensation plan. Anthem allocates a share of the total accumulated costs of this plan to the Company based on the number of allocated employees subject to the deferred compensation plan. The Company has no legal obligation for benefits under this plan.

The Company participates in the Anthem 401(k) Plan, sponsored by ATH Holding Company, LLC ("ATH Holding") and covering substantially all employees. Voluntary employee contributions are matched by ATH Holding subject to certain limitations. ATH Holding allocates a share of the total accumulated costs of this plan to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

The Company participates in a stock incentive compensation plan, sponsored by Anthem, providing incentive awards to non-employee directors and employees, consisting of Anthem stock options, restricted stock, restricted stock units, stock appreciation rights, performance shares, and performance units. Anthem allocates a share of the total share-based compensation expense of this plan to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

During 2020 and 2019, the Company was allocated the following costs or (credits) for these retirement benefits:

	 2020	2019
Deferred compensation plan	\$ 42,606 \$	52,455
Defined contribution plan	2,970,597	2,104,417
Stock incentive compensation plan	2,386,606	1,750,390

H. Post Employment Benefits and Compensated Absences

Not applicable.

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

Not applicable.

13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations

A. Outstanding Shares

As of December 31, 2020, the Company has 1,000 shares of \$.01 par value common stock authorized, issued and outstanding.

B. Preferred Stock

The Company has no preferred stock outstanding.

C. Dividend Restrictions

Under Iowa code 521A.5, A domestic insurer shall not pay any extraordinary dividend or make any other extraordinary distribution to its shareholders until thirty days after the commissioner has received notice of the declaration of the dividend or distribution and has not disapproved such payment within the period, or until the time the commissioner has approved the payment within the thirty-day period. For purposes of this paragraph, an "extraordinary dividend or distribution" includes any dividend or distribution of cash or other property, whose fair market value together with that of other dividends or distributions made within the preceding twelve months exceeds the greater of the following: (1) Ten percent of insurer's surplus as regards policyholders as the thirty-first day of December next preceding. (2) The net gain from operations of the insurer, if the insurer is a life insurer, or the net income, if the insurer is not a life insurer, for the twelve-month period ending the thirty-first day of December next preceding.

D. Dividends Paid

See Footnote 10B.

E. Maximum Ordinary Dividend During 2021

Within the limitations of (C) above, the Company may pay \$43,588,845 in ordinary dividends during 2021 without restrictions, other than state notification requirements.

F. Unassigned Surplus Restrictions

Unassigned surplus funds are not restricted at December 31, 2020.

G. Mutual Surplus Advances

Not applicable.

H. Company Stock Held for Special Purpose

There are no shares of stock held for special purposes at December 31, 2020.

I. Changes in Special Surplus Funds

The change in balances of special surplus funds from the prior year are due to changes in the amounts segregated for the estimated Affordable Care Act ("ACA") health insurer fee to be paid in the subsequent year. The annual fee under section 9010 of the ACA has been permanently suspended beginning in 2021.

J. Changes in Unassigned Funds

The portion of unassigned funds represented by cumulative unrealized investment losses was (\$36,074) at December 31, 2020.

K. Surplus Notes

The Company has not issued any surplus notes or debentures or similar obligations.

L. Restatement due to Prior Quasi-reorganizations

The Company had no restatements due to prior quasi-reorganizations.

M. Quasi-reorganizations over Prior 10 Years

The Company has not been involved in a quasi-reorganization during the past 10 years.

14. Liabilities, Contingencies and Assessments

A. Contingent Commitments

The Company had no contingent commitments at December 31, 2020 or 2019.

B. Assessments

- (1) The Company is subject to guaranty fund and other assessments by the state in which it writes business. Guaranty fund assessments are accrued at the time of insolvencies. Other assessments are accrued either at the time of the assessment or at the time the losses are incurred.
- (2) Not applicable.
- (3) Not applicable.

C. Gain Contingencies

The Company has no gain contingencies at December 31, 2020 or 2019.

D. Claims-Related Extra Contractual Obligation and the Bad Faith Losses Stemming From Lawsuits

Not applicable.

E. Joint and Several Liabilities

Not applicable.

F. All Other Contingencies

Litigation and regulatory proceedings

Cigna Corporation Merger Litigation

In July 2015, Anthem and Cigna Corporation, or Cigna, announced that they entered into the Cigna Agreement and Plan of Merger, or Cigna Merger Agreement, pursuant to which Anthem would acquire all outstanding shares of Cigna. In July 2016, the U.S. Department of Justice or DOJ, along with certain state attorneys general, filed a civil antitrust lawsuit in the U.S. District Court for the District of Columbia, or District Court, seeking to block the merger. In February 2017, Cigna purported to terminate the Cigna Merger Agreement and commenced litigation against Anthem in the Delaware Court of Chancery, or Delaware Court, seeking damages, including \$1,850,000,000 termination fee pursuant to the terms of the Cigna Merger Agreement, and a declaratory judgement that its purported termination of the Cigna Merger Agreement was lawful, among other claims, which is captioned *Cigna Corp. v. Anthem Inc.*

Also in February 2017, Anthem initiated their own litigation against Cigna in the Delaware Court seeking a temporary restraining order to enjoin Cigna from terminating the Cigna Merger Agreement, specific performance compelling Cigna to comply with the Cigna Merger Agreement and damages, which is captioned *Anthem Inc. v. Cigna Corp.* In April 2017, the U.S. Circuit Court of Appeals for the District of Columbia affirmed the ruling of the District Court, which blocked the merger. In May 2017, after the Delaware Court denied Anthem's motion to enjoin Cigna from terminating the Cigna Merger Agreement, Anthem delivered to Cigna a notice terminating the Cigna Merger Agreement.

In the Delaware court litigation, trial commenced in late February 2019 and concluded in March 2019. The Delaware Court held closing arguments in November 2019 and took the matter under consideration. In February 2020, the Delaware Court requested supplemental briefing, which has been submitted. On August 31, 2020, the Delaware Court issued an opinion finding that neither party was owed damages and that Anthem did not owe Cigna the \$1,850,000,000 termination fee. The Delaware Court issued an order implementing its opinion in October 2020. Cigna filed its notice of appeal in November 2020 challenging the trial court's opinion that Anthem did not owe Cigna a termination fee. Cigna filed its appellate brief in December 2020. Anthem's response was filed in January. Anthem believes Cigna's allegations are without merit and they intend to vigorously defend against Cigna's allegations; however, the ultimate outcome of any appeal of this litigation with Cigna cannot be presently determined.

In October 2018, a shareholder filed a derivative lawsuit in the State of Indiana Marion County Superior Court, captioned *Henry Bittmann, Derivatively, et al. v. Joseph R. Swedish, et al.*, purportedly on behalf of Anthem and their shareholders against certain current and former directors and officers alleging breaches of fiduciary duties, unjust enrichment and corporate waste associated with the Cigna Merger Agreement. This case has been stayed at the request of the parties pending the outcome of Anthem's litigation with Cigna in the Delaware Court. This lawsuit's ultimate outcome cannot be presently determined.

Other Contingencies

From time to time, the Company is party to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. The Company, like HMOs and health insurers generally, excludes certain healthcare and other services from coverage under our HMO, PPO, and other plans. The Company is, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on the Company. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.

In addition to the lawsuits described above, the Company is also involved in other pending and threatened litigation of the character incidental to their business, and is from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on the Company's business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on the Company's financial position or results of operations.

The Company is involved in pending and threatened litigation of the character incidental to the business transacted, arising out of its operations and is from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits and reviews and administrative proceedings include routine and special investigations by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on the Company's business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on the Company's financial position or results of operations.

The Company has no other known material contingencies.

Provisions for uncollectible amounts

At December 31, 2020 and 2019, the Company reported admitted assets of \$125,397,120 and \$67,257,772, respectively, in premium receivables and receivables due from uninsured plans. These receivables are not deemed to be uncollectible, therefore, no additional provision for uncollectible amounts has been recorded. The potential for any additional loss is not believed to be material to the Company's financial condition.

15. Leases

A. Lessee Operating Lease

(1) The Company leases office space, office equipment, EDP equipment, and software under various noncancelable operating leases. Certain leases have the right to renew. There are no escalation clauses for any lease. Related lease expense for 2020 and 2019 was \$658,576 and \$640,641, respectively.

During the third quarter of 2020, the Company reevaluated its future office space needs and determined that it would permanently cease use of space under certain

operating leases. At December 31, 2020, the Company has recorded a liability for lease exit costs of \$24,648.

(2) At December 31, 2020, the minimum aggregate rental commitments are as follows:

	Year Ending December 31	Oper	ating Leases
1	2021	\$	115,400
2	2022		—
3	2023		—
4	2024		—
5	2025		—
6	Total	\$	115,400

(3) The Company has not entered into any material sale-leaseback transactions.

B. Lessor Leases

- (1) The Company has not entered into any operating leases.
- (2) The Company has not entered into any leveraged leases.

16. Information About Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk

The Company has no significant financial instruments with off-balance sheet risk.

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of investment securities. All investment securities are managed by professional investment managers within policies authorized by the board of directors. Such policies limit the amounts that may be invested in any one issuer and prescribe certain investee company criteria. As of December 31, 2020, there were no significant concentrations.

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

Not applicable at December 31, 2020 and 2019.

B. Transfer and Servicing of Financial Assets

- (1) The Company participates in a securities lending program whereby marketable securities in its investment portfolio are transferred to independent brokers or dealers. At December 31, 2020 the fair value of securities loaned was \$35,249,309 and the carrying value of securities loaned was \$33,305,205.
- (2) (7) Not applicable.

C. Wash Sales

- (1) In the course of the Company's asset management, securities may be sold and reacquired within 30 days of the sale date to enhance the yield on the investments.
- (2) At December 31, 2020 and 2019, there were no wash sales involving securities with an NAIC designation of 3 or below or unrated.

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

A. Administrative Services Only ("ASO") Plans

The gain or (loss) from operations from ASO uninsured plans and the uninsured portion of partially insured plans during 2020 was:

		AS	U O Uninsured Plans	Ininsured Portion of Partially Insured Plans	Total ASO
a.	Net reimbursement for administrative expenses (including administrative fees) in excess of (less than) actual expenses	\$	(799,794) \$	— \$	(799,794)
b.	Total net other income or expenses (including interest paid to or received from plans)		_	_	_
c.	Net gain or (loss) from operations	\$	(799,794) \$	— \$	(799,794)
d.	Total claim payment volume	\$	41,547,759 \$	— \$	41,547,759

B. Administrative Services Contract ("ASC") Plans

Not applicable.

C. Medicare or Other Similarly Structured Cost-Based Reimbursement Contract

- (1) The Company does not record revenue explicitly attributable to the cost share and reinsurance components of administered Medicare products.
- (2)

Receivable from	Related to	2020	0	2019
Centers for Medicare and Medicaid Services	Cost share and reinsurance components of administered Medicare products	\$	— \$	_
U.S. Department of Health and Human Services	Cost share and reinsurance components of administered commercial ACA products	\$	— \$	
Uninsured plans	Uninsured business, not including pharmaceutical rebate receivables	\$	— \$	6,598,000

- (3) As no revenue is recorded in connection with the cost share and reinsurance components of the Company's Medicare and ACA products, the Company has recorded no allowances and reserves for the adjustment of recorded revenues and receivables.
- (4) The Company has made no adjustment to revenue resulting from the audit of costreimbursement receivables related to revenues recorded in the prior period.

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

No premiums were written by managing general agents or third party administrators during the years ended December 31, 2020 and 2019.

20. Fair Value Measurements

- А.
- (1) Fair Value Measurements at Reporting Date

Description for each class of asset or liability	(Le	evel 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Total
Bonds						
U.S. special revenues	\$	_	\$ 1,161,300	\$	\$ _ \$	5 1,161,300
Industrial and misc			919,949	_	_	919,949
Total bonds	\$	_	\$ 2,081,249	\$ —	\$ _ \$	5 2,081,249
Total assets at fair value/NAV	\$		\$ 2,081,249	\$ _	\$ _ \$	5 2,081,249

(2) Fair Value Measurements in (Level 3) of the Fair Value Hierarchy

There are no investments in Level 3 as of December 31, 2020 and 2019.

- (3) The Company's policy is to recognize transfers between Levels, if any, as of the beginning of the reporting period.
- (4) Fair values of bonds are based on quoted market prices, where available. These fair values are obtained primarily from third party pricing services, which generally use Level 1 or Level 2 inputs, for the determination of fair value to facilitate fair value measurements and disclosures. Level 2 securities primarily include United States government securities, corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. The Company has controls in place to review the pricing services' qualifications and procedures used to determine fair values. In addition, the Company periodically reviews the pricing services' pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable.

Certain bonds, primarily corporate debt securities, are designated Level 3. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.

There have been no significant changes in the valuation techniques during the current period.

B. Fair Value Measurements Under Other Accounting Pronouncements

Not applicable at December 31, 2020 and 2019.

C. Financial Instruments

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds	\$742,876,267	\$ 713,695,490	\$ 82,965,046	\$659,911,221	\$ —	\$ —	\$ —
Securities Lending Collateral	35,989,289	35,989,072	_	35,989,289	_	_	_

D. Not Practicable to Estimate Fair Value

There are no financial instruments that were not practicable to estimate fair value.

E. Investments Measured at Net Asset Value

The Company has no investments measured at net asset value.

21. Other Items

A. Unusual or Infrequent Items

The spread of the COVID-19 virus caused significant financial market volatility, economic uncertainty, and interruptions to normal business activities. The ultimate impact to the Company is unknown, but management expects continued interruptions to day-to-day business activities, impacts to claim and premium activity, investment values, as well as possible impacts to liquidity.

B. Troubled Debt Restructuring: Debtors

Not applicable at December 31, 2020 and 2019.

C. Other Disclosures

Not applicable at December 31, 2020 and 2019.

D. Business Interruption Insurance Recoveries

The Company has reported no recoveries for business interruption for the years ended December 31, 2020 and 2019.

E. State Transferable and Non-Transferable Tax Credits

The Company did not have state transferable or non-transferable tax credits at December 31, 2020 and 2019.

F. Subprime Mortgage-Related Risk Exposure

(1) The Company's investment strategy of providing safety and preservation of capital, sufficient liquidity to meet cash flow requirements and the attainment of a competitive after-tax investment return is supported by a well diversified portfolio consisting of many different types of investments. The portion of the Company's investment portfolio with subprime mortgage-related risk exposure is relatively small in comparison to the overall investment portfolio, and consists mainly of investment grade securities with no exposure to collateralized debt obligations. All mortgage related investments are monitored closely as part of the quarterly investment review performed by the Anthem Investment Impairment Review Committee.

- (2) The Company did not carry investments in subprime mortgage loans in its portfolio at December 31, 2020 or 2019.
- (3) The Company did not have subprime mortgage-related risk exposure at December 31, 2020 or 2019.
- (4) The Company did not underwrite Mortgage Guaranty or Financial Guaranty insurance coverage at December 31, 2020 or 2019.

G. Retained Assets

The Company does not have retained assets at December 31, 2020 and 2019.

H. Insurance-Linked Securities Contracts

Not applicable.

I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy

Not applicable.

22. Events Subsequent

The Company is subject to an annual fee under section 9010 of the ACA. A health insurance company's portion of the annual fee becomes payable once the entity provides health insurance for any U.S. health risk for each calendar year beginning on or after January 1 of the year the fee is due. The annual fee under section 9010 of the ACA was permanently suspended beginning in 2021.

		Current Year	 Prior Year
A. Did the reporting entity write accident and health insuran premium that is subject to Section 9010 of the Federal Affordable Care Act (YES/NO)?	ice	YES	
B. ACA fee assessment payable for the upcoming year	\$	—	\$ 37,039,805
C. ACA fee assessment paid	\$	38,411,881	\$ _
D. Premium written subject to ACA 9010 assessment	\$		\$ 1,527,760,066
E. Total Adjusted Capital before surplus adjustment (Five-Y Historical Line 14)	rear \$	494,588,845	
F. Total Adjusted Capital after surplus adjustment (Five-Yer Historical Line 14 minus Line 22B above).	ear \$	494,588,845	
G. Authorized Control Level (Five-Year Historical Line 15)	\$	114,999,050	
H. Would reporting the ACA assessment as of December 31 2018 have triggered an RBC action level (YES/NO)?	,	No	

Subsequent events have been considered through February 25, 2021 for the statutory statement issued on February 26, 2021. There were no events occurring subsequent to December 31, 2020 requiring recognition or disclosure.

23. Reinsurance

A. Ceded Reinsurance Report

Section 1 - General Interrogatories

(1) Are any of the reinsurers that are listed in Schedule S as non-affiliated owned in excess of 10% or controlled, either directly or indirectly, by the Company or by any representative, officer, trustee, or director of the Company?

Yes () No (X)

If yes, give full details.

(2) Have any policies issued by the Company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10% or controlled, directly or indirectly, by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?

Yes () No (X)

If yes, give full details.

Section 2 - Ceded Reinsurance Report - Part A

(1) Does the Company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credits?

Yes () No (X)

If yes, give full details.

(2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes () No (X)

If yes, give full details.

Section 3 - Ceded Reinsurance Report - Part B

(1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the Company may consider the current or anticipated experience of the business reinsured in making this estimate. <u>\$0</u>

(2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the Company as of the effective date of the agreement?

Yes () No (X)

If yes, give full details.

B. Uncollectible Reinsurance

The Company has no uncollectible reinsurance at December 31, 2020 and 2019.

C. Commutation of Ceded Reinsurance

The Company has not commuted ceded reinsurance during 2020 and 2019.

D. Certified Reinsurer Rating Downgraded or Status Subject Revocation

The Company has no downgraded certified reinsurer ratings or status subject to revocations during 2020 and 2019.

E. Reinsurance Credit

- (1) Not applicable.
- (2) Not applicable.
- (3) Not applicable.
- (4) Not applicable.
- (5) Not applicable.

24. Retrospectively Rated Contracts & Contracts Subject to Redetermination

- **A.** The Company sells accident and health policies for which the premiums vary based on loss experience. The Company estimates retrospective premium adjustments through the review of each retrospectively rated account, comparing the claim development with that anticipated in the policy contracts.
- **B.** The Company records accrued retrospective premium as an adjustment to earned premium.
- C. 100% of the net premium written is subject to retrospective ratings features.
- **D.** Not applicable.
- E. Risk-Sharing Provisions of the ACA
 - (1) Did the reporting entity write accident and health insurance premium that is subject to the Affordable Care Act risk-sharing provisions (YES/NO)? <u>No</u>
 - (2) Impact of Risk-Sharing Provisions of the Affordable Care Act on Admitted Assets, Liabilities and Revenue for the Current Year

Not applicable.

(3) Roll-forward of prior year ACA risk-sharing provisions for the following asset (gross of any nonadmission) and liability balances, along with the reasons for adjustments to prior year balance.

Not applicable.

(4) Roll-forward of Risk Corridors Asset and Liability Balances by Program Benefit Year.

Not applicable.

(5) ACA Risk Corridors Receivable as of Reporting Date.

Not applicable.

25. Change in Incurred Claims and Claim Adjustment Expenses

- **A.** The estimated cost of claims and claim adjustment expense attributable to insured events of prior years increased by \$4,842,118 during 2020. This is approximately 1.6% of unpaid claims and claim adjustment expenses of \$305,942,598 as of December 31, 2019. The deficiency reflects the increases in estimated claims and claims adjustment expenses as a result of claims payment during the year, and as additional information is received regarding claims incurred prior to 2020. Recent claim development trends are also taken into account in evaluating the overall adequacy of unpaid claims and unpaid claim adjustment expense.
- **B.** There were no significant changes in methodologies and assumptions used in calculating the liability for unpaid losses and loss adjustment expenses.

26. Intercompany Pooling Arrangements

Not applicable at December 31, 2020 and 2019.

27. Structured Settlements

Not applicable at December 31, 2020 and 2019.

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

During 2020, the Company sold \$59,694 of pharmaceutical rebate receivables without recourse to Blue Cross of California, an affiliated entity. The cash proceeds received by the Company represented the expected pharmaceutical rebates recoverable in 90 days or more at the end of each quarter, less a (\$298) discount fee.

Quarter	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received Within 90 Days of Billing	Actual Rebates Received Within 91 to 180 Days of Billing	Actual Rebates Received More Than 180 Days After Billing
12/31/2020	\$ —	\$ —	\$	\$	\$
9/30/2020	1,458,183	263,528	_		
6/30/2020		250,059	102,629	_	_
3/31/2020	2,093,157	358,289	343,011		_
12/31/2019	152,244	911,176	1,881,534	_	_
9/30/2019	71,982	180,295	115,477	_	178,549
6/30/2019	17,284	80,226	—	79,170	208
3/31/2019	45,787	73,073	_	72,447	(193)
12/31/2018	23,680	53,936		53,613	474
9/30/2018	31,892	55,072	44,796	14,144	(1,714)
6/30/2018	102,367	71,924	26,573	59,780	(2,485)
3/31/2018	103,943	125,751	47,297	84,083	(2,427)

B. Risk Sharing Receivables

Not applicable at December 31, 2020 and 2019.

29. Participating Policies

Not applicable at December 31, 2020 and 2019.

30. Premium Deficiency Reserves

The Company had no liabilities related to premium deficiency reserves as of December 31, 2020 and 2019.

31. Anticipated Salvage and Subrogation

The Company took into account estimated anticipated subrogation and other recoveries in its determination of the liability for unpaid claims and reduced the liability by \$4,191,000 and \$2,538,000 at December 31, 2020 and 2019, respectively.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES

GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company System consist is an insurer? If yes, complete Schedule Y, Parts 1, 1A and 2							
1.2	If yes, did the reporting entity register and file with its domiciliary State Insurance C such regulatory official of the state of domicile of the principal insurer in the Holding providing disclosure substantially similar to the standards adopted by the National its Model Insurance Holding Company System Regulatory Act and model regulatio subject to standards and disclosure requirements substantially similar to those substantially similar to those requirements substantially similar to those subst	g Company System, a regis Association of Insurance C ns pertaining thereto, or is t	stration statement ommissioners (NAIC) in the reporting entity	Yes [)	(] No [] N/A []		
1.3	State Regulating?				low	a		
1.4	Is the reporting entity publicly traded or a member of a publicly traded group?				Yes [X] No []		
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the	e SEC for the entity/group.			000115	6039		
2.1	Has any change been made during the year of this statement in the charter, by-law reporting entity?				Yes [] No [X]		
2.2	If yes, date of change:							
3.1	State as of what date the latest financial examination of the reporting entity was ma	ade or is being made		·	12/31/	2017		
3.2	State the as of date that the latest financial examination report became available fr entity. This date should be the date of the examined balance sheet and not the date				12/31/	2017		
3.3	State as of what date the latest financial examination report became available to o domicile or the reporting entity. This is the release date or completion date of the e examination (balance sheet date).	xamination report and not t	he date of the	- <u>-</u>	10/30/	2019		
3.4	By what department or departments? Iowa Insurance Division							
3.5	Have all financial statement adjustments within the latest financial examination rep statement filed with Departments?	ort been accounted for in a	subsequent financial	Yes [] No [] N/A [X]		
3.6	Have all of the recommendations within the latest financial examination report bee	n complied with?		Yes [] No [] N/A [X]		
4.1 4.2	4.12 renewals? During the period covered by this statement, did any sales/service organization ow	eporting entity), receive cre n direct premiums) of: siness? ned in whole or in part by th	edit or commissions for o	control] No[X]] No[X]		
		siness?] No [X]		
5.1	Has the reporting entity been a party to a merger or consolidation during the period If yes, complete and file the merger history data file with the NAIC.				-] No[X]] No[X]		
5.2	If yes, provide the name of the entity, NAIC Company Code, and state of domicile ceased to exist as a result of the merger or consolidation.	(use two letter state abbrev	iation) for any entity that	has				
	1 Name of Entity	2 NAIC Company Code	3 State of Domicile					
6.1	Has the reporting entity had any Certificates of Authority, licenses or registrations (revoked by any governmental entity during the reporting period?	including corporate registra	ation, if applicable) suspe		Yes [] No [X]		
6.2	If yes, give full information:							
7.1	Does any foreign (non-United States) person or entity directly or indirectly control 1	0% or more of the reporting	g entity?		Yes [] No [X]		
7.2	If yes, 7.21 State the percentage of foreign control;					%		
	 7.22 State the nationality(s) of the foreign person(s) or entity(s) or if the entity is a rattorney-in-fact; and identify the type of entity(s) (e.g., individual, corporation of the entity is a rattorney-in-fact; 	nutual or reciprocal, the na	tionality of its manager o			/0		
	1 Nationality	2 Type of Er						

GENERAL INTERROGATORIES

8.1 8.2	Is the company a subsidiary of a bank holding company regulated by the Federal Reserve Board? If response to 8.1 is yes, please identify the name of the bank holding company.					Yes []	No [[X]
8.3 8.4	Is the company affiliated with one or more banks, thrifts or securities firms? If response to 8.3 is yes, please provide below the names and location (city and state of the main office) of any affiliates regulated by a federal regulatory services agency [i.e. the Federal Reserve Board (FRB), the Office of the Comptroller of the Currency (OCC), the Federal Deposit Insurance Corporation (FDIC) and the Securities Exchange Commission (SEC)] and identify the affiliate's primary federal regulator.				eral	Yes []	No [[X]
	1 Affiliate Name	2 Location (City, State)	3 FRB C	4 DCC	5 FDIC	6 SEC	_		
9.	What is the name and address of the independent certified public acc	0	nnual audi	t?			_		
10.1	Ernst & Young LLP, 111 Monument Circle Suite 4000, Indianapolis, IN Has the insurer been granted any exemptions to the prohibited non-au requirements as allowed in Section 7H of the Annual Financial Report law or regulation?	udit services provided by the certified independent p ting Model Regulation (Model Audit Rule), or substa	ntially simil	ar stat	e	Yes []	No [[X]
10.2	If the response to 10.1 is yes, provide information related to this exem	iption:							
10.3 10.4	Has the insurer been granted any exemptions related to the other requallowed for in Section 18A of the Model Regulation, or substantially sin If the response to 10.3 is yes, provide information related to this exem	uirements of the Annual Financial Reporting Model I milar state law or regulation? ption:	Regulation	as		Yes []	No [[X]
10.5	Has the reporting entity established an Audit Committee in compliance					1 No [1	N//	۲ I Δ
10.6	If the response to 10.5 is no or n/a, please explain				50 [A] 110 [,	1477	
11.	What is the name, address and affiliation (officer/employee of the reporting) of the individual providing the statement of actuarial opinion/certi Adrian Rosen, FSA, MAAA, Actuarial Director, 2016 Raven Way, Cha	fication?	n actuarial o	consul	-				
12.1	Does the reporting entity own any securities of a real estate holding co	ompany or otherwise hold real estate indirectly?				Yes []	No [[X]
		estate holding company							
	•	ircels involved							
12.2	If, yes provide explanation: 12.13 Total book/ad	justed carrying value				\$			
13.	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTIT	IES ONLY:							
13.1	What changes have been made during the year in the United States n	nanager or the United States trustees of the reporting	ng entity?						
13.2	Does this statement contain all business transacted for the reporting e	entity through its United States Branch on risks wher	rever locate	ed?		Yes []	No [[]
13.3	Have there been any changes made to any of the trust indentures dur	ing the year?				Yes []	No [[]
13.4	If answer to (13.3) is yes, has the domiciliary or entry state approved the] No []	N//	A[]
14.1	Are the senior officers (principal executive officer, principal financial of similar functions) of the reporting entity subject to a code of ethics, wh a. Honest and ethical conduct, including the ethical handling of actual relationships; b. Full, fair, accurate, timely and understandable disclosure in the peri	ich includes the following standards? or apparent conflicts of interest between personal a iodic reports required to be filed by the reporting enti	nd profess			Yes [)	(]	No ((1
	 c. Compliance with applicable governmental laws, rules and regulation d. The prompt internal reporting of violations to an appropriate person 								
	e. Accountability for adherence to the code.								
14.11	If the response to 14.1 is No, please explain:								
	Has the code of ethics for senior managers been amended?					Yes []	No ([X]
14.21	If the response to 14.2 is yes, provide information related to amendme	ent(s).							
	Have any provisions of the code of ethics been waived for any of the s If the response to 14.3 is yes, provide the nature of any waiver(s).					Yes []	No ([X]

GENERAL INTERROGATORIES

]	No []	X]
15.2	bank of the Letter of Credit and describe the circumstances in which the Letter of Credit is triggered.								
	1	2		3			4		
	American Bankers								
	Association (ABA) Routing								
	Number	Issuing or Confirming Bank Name	Circumstances	That Can Trigger the Letter of Credit		A	moun	nt	
					<u></u>		<u></u>		
		BOARD OI		S					
16.	Is the purchase of thereof?	or sale of all investments of the reporting entity passed upon e	ither by the board o	of directors or a subordinate committee	Э	Yes [XI	No [1
17.	Does the reportir	ng entity keep a complete permanent record of the proceeding	s of its board of dir	ectors and all subordinate committees	6	Yes [-	-	1
18.	Has the reporting	gentity an established procedure for disclosure to its board of officers, directors, trustees or responsible employees that is in	directors or trustee	es of any material interest or affiliation	on the	Yes [-	-]
		FIN							
19.		nt been prepared using a basis of accounting other than State	utory Accounting Pr			Yes [1	No [V I
20.1		iples)? ned during the year (inclusive of Separate Accounts, exclusiv				-	-	-	-
			,	20.12 To stockholders not officers					
				20.13 Trustees, supreme or grand (Fraternal Only)		\$			
20.2		oans outstanding at the end of year (inclusive of Separate Ac	counts, exclusive o						
	policy loans):			20.21 To directors or other officers 20.22 To stockholders not officers					
				20.23 Trustees, supreme or grand					
21.1	Woro onv oposto	reported in this statement subject to a contractual obligation	to transfor to anoth	(Fraternal Only)		\$			
21.1	obligation being	reported in the statement?				Yes []	No []	X]
21.2	If yes, state the a	mount thereof at December 31 of the current year:		21.21 Rented from others					
				21.22 Borrowed from others 21.23 Leased from others					
				21.23 Leased from others		ֆ Տ			
22.1	Does this statem	ent include payments for assessments as described in the Ar tion assessments?	nual Statement Ins	structions other than guaranty fund or					
22.2	If answer is yes:			2.21 Amount paid as losses or risk adj					
				2.22 Amount paid as expenses					
00.4	Deee the second			2.23 Other amounts paid					
23.1 23.2		ng entity report any amounts due from parent, subsidiaries or ny amounts receivable from parent included in the Page 2 am							
	-								
		INVE	STMENT						
24.01		ks, bonds and other securities owned December 31 of currer ssion of the reporting entity on said date? (other than securities				Yes [X]	No []
24.02	, 0	d complete information relating thereto							
24.03	whether collatera	nding programs, provide a description of the program including al is carried on or off-balance sheet. (an alternative is to refere nd 17.	nce Note 17 where	e this information is also provided)					
24.04	For the reporting Instructions.	entity's securities lending program, report amount of collatera	al for conforming pro	ograms as outlined in the Risk-Based	Capital	\$.35,98	9,072
24.05	For the reporting	entity's securities lending program, report amount of collatera	al for other program	S		\$			
24.06		ities lending program require 102% (domestic securities) and tract?			Yes [X] No]	N/A	[]
24.07	Does the reportir	ng entity non-admit when the collateral received from the cour	nterparty falls below	/ 100%?	Yes [X] No	. 1	N/A	[]
24.08		ng entity or the reporting entity 's securities lending agent utilizes lending?			Yes [X] No]	N/A	[]

GENERAL INTERROGATORIES

24.09 For the reporting entity's securities lending program state the amount of the following as of December 31 of the current year:

	24.091 Total fair value of reinvested collateral assets report	ted on Schedule DL, Parts 1 and 2.	\$
	24.092 Total book adjusted/carrying value of reinvested co	Ilateral assets reported on Schedule DL, Parts 1 and 2	\$
	24.093 Total payable for securities lending reported on the	liability page.	\$
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
25.1	Were any of the stocks, bonds or other assets of the reporting entity owned control of the reporting entity, or has the reporting entity sold or transferred force? (Exclude securities subject to Interrogatory 21.1 and 24.03).	any assets subject to a put option contract that is currently in	Yes [] No [X]
25.2	If yes, state the amount thereof at December 31 of the current year:	25.21 Subject to repurchase agreements	\$
		25.22 Subject to reverse repurchase agreements	\$
		25.23 Subject to dollar repurchase agreements	
		25.24 Subject to reverse dollar repurchase agreements	
		25.25 Placed under option agreements	
		25.26 Letter stock or securities restricted as to sale -	
		excluding FHLB Capital Stock	\$
		excluding FHLB Capital Stock	\$
		25.28 On deposit with states	\$
		25.29 On deposit with other regulatory bodies	\$
		25.30 Pledged as collateral - excluding collateral pledge an FHLB	ed to
		25.31 Pledged as collateral to FHLB - including assets backing funding agreements	\$
		25.32 Other	\$

25.3 For category (25.26) provide the following:

	1 Nature of Restriction	2 Description		3 ount	
26.1	Does the reporting entity have any hedging transactions reported on Sc	shedule DB?	Yes [] N	lo [X]
26.2	If yes, has a comprehensive description of the hedging program been m If no, attach a description with this statement.	nade available to the domiciliary state? Yes [] No []	N/A [
LINES 2	26.3 through 26.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONI	LY:			
26.3	Does the reporting entity utilize derivatives to hedge variable annuity gu	arantees subject to fluctuations as a result of interest rate sensitivity?	Yes [] N	lo [X]
26.4	26.42 Per 26.43 Oth	ecial accounting provision of SSAP No. 108 mitted accounting practice er accounting guidance	Yes [j N	lo [] lo [] lo []
26.5	 reserves and provides the impact of the hedging strategy within Financial Officer Certification has been obtained which indicate 	miciliary state. is consistent with the requirements of VM-21. he hedging strategy is incorporated within the establishment of VM-21	Yes [] N	lo []
27.1	Were any preferred stocks or bonds owned as of December 31 of the c issuer, convertible into equity?	current year mandatorily convertible into equity, or, at the option of the	Yes [] N	lo [X]
27.2	If yes, state the amount thereof at December 31 of the current year		\$		
28.	Excluding items in Schedule E - Part 3 - Special Deposits, real estate, r offices, vaults or safety deposit boxes, were all stocks, bonds and other custodial agreement with a qualified bank or trust company in accordan Outsourcing of Critical Functions, Custodial or Safekeeping Agreement	securities, owned throughout the current year held pursuant to a	Yes [)	(] N	lo []
28 01	For agreements that comply with the requirements of the NAIC Financia	al Condition Examiners Handbook, complete the following:			

28.01 For agreements that comply with the requirements of the NAIC Financial Condition Examiners Handbook, complete the following:

1	2
Name of Custodian(s)	Custodian's Address
JP Morgan Chase Bank, N.A	383 Madison Ave, New York, NY 10179

GENERAL INTERROGATORIES

28.02 For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location and a complete explanation:

1	2	3
Name(s)	Location(s)	Complete Explanation(s)

1	2	3	4
Old Custodian	New Custodian	Date of Change	Reason

Yes [] No [X]

Yes [] No [X]

28.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1	2
Name of Firm or Individual	Affiliation
Anthem, Inc.	I
Wells Capital Management	U

28.06 For those firms or individuals listed in the table for 28.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1	2	3	4	5
				Investment
				Management
Central Registration Depository Number				Agreement
Depository Number	Name of Firm or Individual	Legal Entity Identifier (LEI)	Registered With	(IMA) Filed
			Securities Exchange	
104973	Wells Capital Management	549300B3H21002L85190	Commission	NO

29.1 Does the reporting entity have any diversified mutual funds reported in Schedule D, Part 2 (diversified according to the Securities and Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5(b)(1)]?

29.2 If yes, complete the following schedule:

Г	1	2	3
		_	Book/Adjusted
	CUSIP #	Name of Mutual Fund	Carrying Value
	29.2999 - Total		0

29.3 For each mutual fund listed in the table above, complete the following schedule:

1	2	3	4
		Amount of Mutual	
		Fund's Book/Adjusted	
		Carrying Value	
	Name of Significant Holding of the	Attributable to the	Date of
Name of Mutual Fund (from above table)	Mutual Fund	Holding	Valuation

GENERAL INTERROGATORIES

Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value. 30.

	1	2	3
			Excess of Statement
			over Fair Value (-), or
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
30.1 Bonds			
30.2 Preferred stocks	0		0
30.3 Totals	713,695,490	742,876,267	29,180,777

30.4 Describe the sources or methods utilized in determining the fair values:

30.4	Describe the sources or methods utilized in determining the fair values:			
	Fair values were obtained from third-party pricing sources. If a security was not priced by a third-party pricing source, internal analytical systems or broker quotes were utilized.			
31.1	Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?	Yes [] No	[X]
31.2	If the answer to 31.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?	Yes [] No	[]
31.3	If the answer to 31.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D: N/A			
32.1 32.2	Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed? If no, list exceptions:	Yes [X] No	[]
33.	 By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security: a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available. b. Issuer or obligor is current on all contracted interest and principal payments. c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal. Has the reporting entity self-designated 5GI securities? 	Yes [] No	[X]
34.	 By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security: a. The security was purchased prior to January 1, 2018. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators. d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO. 	Yes [] No	[X]
35.	 By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund: a. The shares were purchased prior to January 1, 2019. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019. d. The fund only or predominantly holds bonds in its portfolio. e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO. f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed. Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria? 	Yes [] No	[X]
36.	 By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following: a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date. b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties. c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review. d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 36.a - 36.c are reported as long-term investments. Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria?] No [X] N/	Ά[]

GENERAL INTERROGATORIES

OTHER

37.1 Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any?.....

37.2 List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to trade associations, service organizations and statistical or rating bureaus during the period covered by this statement.

1	2
Name	Amount Paid

38.1 Amount of payments for legal expenses, if any?

38.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal expenses during the period covered by this statement.

1	2
Name	Amount Paid
Reed Smith, LLP	
	, , , , , , , , , , , , , , , , , , ,

39.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures in connection with matters before legislative bodies, officers or departments of government during the period covered by this statement.

1	2
Name	Amount Paid
Kyle Carlson	
Carney & Appleby	
Lobbying expenses disclosed reflect amounts reported in the Lobbyist Disclosure Reports filed with the Secretary of State as well as the cost of external contractors who provided lobbying services to the Company. The amount may include expenses that may have been paid by an affiliate on behalf of the Company and, as a result, may not be included in the Underwriting Gain reported on page 4 of the 2020 Annual Statement.	

.....1,140,701

\$

....\$

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

 1.1 Does the reporting entity have any direct Medicare Supplement Insurance in force 1.2 If yes, indicate premium earned on U.S. business only. 1.3 What portion of Item (1.2) is not reported on the Medicare Supplement Insurance 1.31 Reason for excluding 		.\$
1.4 Indicate amount of earned premium attributable to Canadian and/or Other Alien n		
1.5 Indicate total incurred claims on all Medicare Supplement Insurance.		.\$0
1.6 Individual policies:	Most current three years:	
	1.61 Total premium earned	.\$0
	1.62 Total incurred claims	.\$0
	1.63 Number of covered lives	0
	All years prior to most current three years:	
	1.64 Total premium earned	.\$0
	1.65 Total incurred claims	.\$0
	1.66 Number of covered lives	0
1.7 Group policies:	Most current three years:	
	1.71 Total premium earned	.\$0
	1.72 Total incurred claims	
	1.73 Number of covered lives	
	All years prior to most current three years:	
	1.74 Total premium earned	
	1.74 Total premium earned 1.75 Total incurred claims	
	1.76 Number of covered lives	
 Health Test: 2.1 Premium Numerator 		
2.2 Premium Denominator		
2.3 Premium Ratio (2.1/2.2)		
2.4 Reserve Numerator		
2.5 Reserve Denominator		
2.6 Reserve Ratio (2.4/2.5)		
returned when, as and if the earnings of the reporting entity permits?3.2 If yes, give particulars:		Yes [] No [X]
4.1 Have copies of all agreements stating the period and nature of hospitals', physicial dependents been filed with the appropriate regulatory agency?	ans', and dentists' care offered to subscribers and	Yes [X] No []
4.2 If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these	agreements include additional benefits offered?	Yes [] No []
5.1 Does the reporting entity have stop-loss reinsurance?		Yes [] No [X]
5.2 If no, explain: No contractual or regulatory obligation to purchase reinsurance.		
5.3 Maximum retained risk (see instructions)	5.31 Comprehensive Medical	\$
	5.32 Medical Only	
	5.33 Medicare Supplement	
	5.34 Dental & Vision	
	5.35 Other Limited Benefit Plan	
	5.36 Other	
 Describe arrangement which the reporting entity may have to protect subscribers hold harmless provisions, conversion privileges with other carriers, agreements w agreements: 	and their dependents against the risk of insolvency including vith providers to continue rendering services, and any other	
Physician and hospital contracts contain provisions, including hold harmless agre insolvency.		
7.1 Does the reporting entity set up its claim liability for provider services on a service	e date basis?	Yes [X] No []
7.2 If no, give details		
8. Provide the following information regarding participating providers:	8.1 Number of providers at start of reporting year . 8.2 Number of providers at end of reporting year	
9.1 Does the reporting entity have business subject to premium rate guarantees?		
9.1 Does the reporting entity have business subject to premium rate guarantees?		¦oo [] เพบ[∧]
9.2 If yes, direct premium earned:	9.21 Business with rate guarantees between 15-36 months. 9.22 Business with rate guarantees over 36 months	

GENERAL INTERROGATORIES

10.1	Does the reporting entity have Incentive Pool, With	nold or Bonus Ar	rangements in its	provider contracts?			Yes []	No [X]
10.2	If yes:		1	0.21 Maximum am	ount navable bonus	ses	¢	26 138 696
10.2	n yes.					nuses		
						olds		
						hholds		
					,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
11.1	Is the reporting entity organized as:							
				11.12 A Medica	al Group/Staff Mode	əl,	Yes []] No [X]
				11.13 An Individ	dual Practice Asso	ciation (IPA), or, .	Yes []] No [X]
				11.14 A Mixed I	Model (combination	n of above)?	Yes [X]	No []
11.2	Is the reporting entity subject to Statutory Minimum						Yes [X]	
11.3	If yes, show the name of the state requiring such m							lowa 229,998,100
11.4	If yes, show the amount required. Is this amount included as part of a contingency res						-	No [X]
11.5 11.6		erve in stockhoid	der s equity?				165 []	
11.0	lowa Code 521F states that Health Maintenance Or	nanizations need	to meet minimum	RBC capital level	s oursuant to the			
	NAIC's risk-based capital instructions	gamzations need						
12.	List service areas in which reporting entity is license	ed to operate:						
			1 Name of Service	- Area				
	Statewid	e						
13.1	Do you act as a custodian for health savings accou	nts?					Yes []	No [X]
	,						100 []	10 [7]
13.2	If yes, please provide the amount of custodial funds	held as of the re	porting date				\$	
13.3	Do you act as an administrator for health savings ad	counts?					Yes []	No [X]
13.4	If yes, please provide the balance of funds administ	ered as of the re	porting date.				\$	
14.1	Are any of the captive affiliates reported on Schedu		orized reinsurers?			Yes [] No [] N/A [X]
14.2	If the answer to 14.1 is yes, please provide the follo	wing:						
	1	2	3	4	Assets	Supporting Reserve	e Credit	
	·	NAIC	Ŭ		5	6	7	
		Company	Domiciliary	Reserve	Letters of	Trust	0.11	
	Company Name	Code	Jurisdiction	Credit	Credit	Agreements	Other	
					<u> </u>			<u></u>
15.	Provide the following for individual ordinary life insu ceded):	rance* policies (l	J.S. business only) for the current yea	ar (prior to reinsura	nce assumed or		
	ucucuj.			15.1 Г)irect Premium Wri	tten	\$	
						IS	-	
						Lives		
		*Ordir	nary Life Insurance	Includes				
	Term(whether full un	derwriting, limite	d underwriting, jet	issue, "short form a	app")			

		Whole Life (whether full underwriting, limited underwriting, jet issue, "short form app")				
		Variable Life (with or without secondary gurarantee)				
		Universal Life (with or without secondary gurarantee)				
		Variable Universal Life (with or without secondary gurarantee)				
16.	Is the reporting entity licensed	or chartered, registered, gualified, eligible or writing business in at least two states?	Yes []	No	[X]
	1 0 9		-	-		
16.1	If no does the reporting entity	assume reinsurance business that covers risks residing in at least one state other than the state o	f			
10.1	domicile of the reporting entity		Yes []	No	[X]
	-155		-	-		

È

28.1

		1 2020	2 2019	3 2018	4 2017	5 2016
	Balance Sheet (Dages 2 and 2)	2020	2019	2010	2017	2010
	Balance Sheet (Pages 2 and 3)	976 595 769			200 660 680	
1.	Total admitted assets (Page 2, Line 28)					
2.	Total liabilities (Page 3, Line 24)		, ,	,,		
3.	Statutory minimum capital and surplus requirement					
4.	Total capital and surplus (Page 3, Line 33)				149,077,117	
	Income Statement (Page 4)					
5.	Total revenues (Line 8)					
6.	Total medical and hospital expenses (Line 18)					
7.	Claims adjustment expenses (Line 20)					
8.	Total administrative expenses (Line 21)					
9.	Net underwriting gain (loss) (Line 24)			7, 197, 408	(74,721,336)	(204,351,755)
10.	Net investment gain (loss) (Line 27)					0
11.	Total other income (Lines 28 plus 29)				0	0
12.	Net income or (loss) (Line 32)				(38,077,009)	(133,347,650)
	Cash Flow (Page 6)					
13.	Net cash from operations (Line 11)				(271,363,439)	(124,478,428)
	Risk-Based Capital Analysis					
14.	Total adjusted capital			169,352,834		
15.	Authorized control level risk-based capital					
	Enrollment (Exhibit 1)					
16.	Total members at end of period (Column 5, Line 7)	420.905	384.154	201,969	190.441	193,856
17.	Total members months (Column 6, Line 7)					
	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0	,,			,,	,,.
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)					
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)				101.2	
00	Cost containment expenses				0.7	4.0
20.	Other claims adjustment expenses					
21.	Total underwriting deductions (Line 23)					
22.						
23.	Total underwriting gain (loss) (Line 24)	6.9			(6.1)	(25.9)
24.	Unpaid Claims Analysis (U&I Exhibit, Part 2B) Total claims incurred for prior years					
24.	(Line 13, Col. 5)					0
25.	Estimated liability of unpaid claims-[prior year (Line 13, Col. 6)]					0
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)	0				
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)	0	0			
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)	0	0			
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)		0	0	0	0
30.	Affiliated mortgage loans on real estate					
31.	All other affiliated					
32.	Total of above Lines 26 to 31			0	0	0
33.	Total investment in parent included in Lines 26 to 31 above.					
	If a party to a merger, have the two most recent years of requirements of SSAP No. 3, Accounting Changes and (f no, please explain:	Correction of Errors?] No []

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS Allocated by States and Territories

			1	<u> </u>	milocaleu Dy	States and T		siness Only			
	States, etc.		Active Status (a)	2 Accident & Health Premiums	3 Medicare Title XVIII	4 Medicaid Title XIX	5 Federal Employees Health Benefits Plan Premiums	6 Life & Annuity Premiums & Other Considerations	7 Property/ Casualty Premiums	8 Total Columns 2 Through 7	9 Deposit-Type Contracts
1.	Alabama	AI	N N	1 Ternidinis			Tremuns	Considerations	Tiemans		Contracto
	Alaska		N							0	
	Arizona		N							0	
	Arkansas		N								
5.	California	CA	N							0	
	Colorado		N							0	
	Connecticut		N							0	
8.	Delaware	DE	N							0	
	District of Columbia .		N							0	
	Florida		N							0	
	Georgia		N							0	
	Hawaii		N							0	
	Idaho		N							0	
	Illinois		N			•••••		•••••		0	
	Indiana		N	75 050 640		2 220 025 700				0 _3,314,084,433	
	lowa Kansas		L N	75,058,643		3,239,025,790				3,314,084,433	
	Kentucky		NNNNN					•••••		0	
	Louisiana		N N	†							
	Maine		N N							۰ ۱	
	Maryland		NNNN							0	
	Massachusetts		N							0	
	Michigan		N							0	
	Minnesota		N							0	
	Mississippi		N							0	
	Missouri		N							0	
27.	Montana	MT	N							0	
28.	Nebraska	NE	N							0	
	Nevada		N							0	
30.	New Hampshire	NH	N							0	
	New Jersey		N							0	
	New Mexico		N							0	
	New York		N							0	
	North Carolina		N							0	
	North Dakota		N							0	
	Ohio		N							0	
	Oklahoma		N							0	
38.	Oregon	OR	N					•••••		0	
	Pennsylvania		N							0	
	Rhode Island		N	•••••••						0	
	South Carolina		N							0	
	South Dakota		N			•••••		•••••		0	
	Tennessee		N							0	
	Texas		N							0	
	Utah		N N							0	
	Vermont		N N	·						U	
	Virginia Washington		N N							0	
48. 49.	West Virginia	VVA	NNNNN							0	
	Wisconsin		NNNNNN	t						U	
	Wyoming		NNN	†						0	
	American Samoa		NN							0	
	Guam		N	 						0	
	Puerto Rico		N.								
	U.S. Virgin Islands		N							0	
	Northern Mariana										
	Islands		N							0	
	Canada	CAN	N	.						0	
58.	Aggregate other	OT		0	0	0	0	0	0	_	_
59.	alien Subtotal		XXX XXX			0 3,239,025,790	0	0		0 3,314,084,433	0 0
	Reporting entity			13,030,043	U	0,200,020,790	U			5, 514, 004, 433	
50.	contributions for Err	nplovee									
	Benefit Plans		XXX							0	
61.	Total (Direct Busines		XXX	75,058,643	0	3,239,025,790	0	0	0	3,314,084,433	0
	DETAILS OF WRITE	E-INS									
58001.			XXX								
58002.			XXX			.					
58003.			XXX			.		ļ			
	Summary of remaining										
	write-ins for Line 58 f		1001	0	^	0	^	0	_	0	_
			XXX		0	·····.0	0	0	0	0	0
	overflow page										
	overflow page Totals (Lines 58001 58003 plus 58998)(L	through									

R - Registered - Non-domiciled RRGs......0 Q - Qualified - Qualified or accredited reinsurer......0


0 ...56

.1


(b) Explanation of basis of allocation by states, premiums by state, etc.

0	BCBSA Licensee
	Regulated Insurance Company
	Regulated BCBSA Licensee


ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED




HealthKeepers, Inc. is owned 92.51% by Anthem Southeast, Inc. and 7.49% by UNICARE National Services, Inc.



2 30.09% of WPMI, LLC is owned by unaffiliated investors




3 ATH Holding Company, LLC holds a 98% interest in Highland Investor Holdings, LLC, and Amerigroup Corporation holds the remaining 2% interest.



⁴ 45% of WCIC is owned by Aurora Health Care, Inc. (non-affiliate). Not consolidated for accounting purposes.


 $_{\rm S}$ Anthem Workers' Compensation LLC is owned 75% by Anthem Blue Cross Life and Health Insurance Company and 25% by HealthLink, Inc.







BCBSA Licensee Regulated Insurance Company Regulated BCBSA Licensee

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED





 7 Amerigroup Corporation holds a 2% interest in Highland Investor Holdings, LLC, and ATH Holding Company, LLC holds the remaining 98% interest.




Inc. and 50% owned by HealthPlus HP, LLC.

¹⁷ Empower Healthcare Solutions, LLC (AR) is owned 16.6% by Beacon Health Options, Inc. and 83.4% by (nonaffiliates)



ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED



¹¹ Community Care Health Plan of Louisiana, Inc. is a joint venture 75% owned by Anthem Partnership Holding Company, LLC and 25% owned by Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana (non-affiliate)

 12 CCHA, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Colorado Community Health Alliance, LLC (non-affiliate)

13 AMH Health, LLC is a joint venture 50% owned by MaineHealth (nonaffiliate) and 50% owned by Anthem Partnership Holding Company, LLC

14 Momentum Health Partners, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Blue Cross and Blue Shield of North Carolina (non-affiliate)

 ${}_{15}$ GR Health Solutions, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Independence Blue Cross, LLC (non-affiliate)

16 Anthem Partnership Holding Company, LLC holds a 95% interest in Community Care Health Plan of Nebraska, Inc., and Blue Cross and Blue Shield of Nebraska, Inc. (non-affiliate) holds the remaining 5%